netFormulary
 Report : A-Z of formulary items 28/02/2020 21:05:00
[Back]
 
Section Name Details
05.01.13 Nitrofurantoin 
06.01.01.02 Abasaglar® Insulin biosimilar glargine 

Retained on formulary for existing patients & those who prefer pen cartridges - first line now Semglee® disposable pens

Abasaglar® 3ml cartridges, disposable pens 100 units/ml KwikPen®

 

 

10.01.03 Abatacept Orencia®

 In line with NICE technology appraisals and local guidance

04.10.01 Acamprosate Campral EC®

 Initiated by Addaction in line with their treatment guidelines 

20 Acapella ® 
02.08.02 Acenocoumarol Sinthrome®
04.08.01 Acetazolamide 

 For ophthalmic use, see glaucoma section (11.6)

Off label use by specialist respiratory team for type 2 respiratory failure

 

11.06 Acetazolamide Diamox®
11.06 Acetazolamide oral liquid 
12.01.01 Acetic Acid 2% Earcalm ®

For self-care & over the counter (OTC) purchase in primary care

11.08.02 Acetylcholine Chloride Miochol-E®
03.07 Acetylcysteine 

Prescribe by brand Oronac® [licensed food supplement]

For pulmonary fibrosis, limited to historic use, specialist initiation. NICE CG163

Nebulised Acetylcysteine is unlicensed and for consultant initiation only. Wye Valley NHS Trust use the injectable preparation via this route. Contact ext 4017 for details.

20 Acetylcysteine 

NOT for new patients: no longer recommended routinely for pulmonary fibrosis, prescribe as Oronac® for existing patients. (see shared care

20 Acetylcysteine 

NOT for new patients: prescribe as Oronac® for existing patients (see shared care)  

11.08.01 Acetylcysteine 5% eye drops  

Mucolytic or filamentary keratitis. Initiation limited to consultant based on slit lamp findings of adherent mucin. Repeat prescription should only be determined by this examination.

11.08.01 Acetylcysteine 5% with Hypromellose 0.35% Ilube®

Mucolytic or filamentary keratitis. Initiation limited to consultant based on slit lamp findings of adherent mucin. Repeat prescription should only be determined by this examination.

05.03.02.01 Aciclovir 

Oral and I.V. preparations

Also see section 11.3.3. for ophthalmic use and 13.10.3 for topical use

11.03.03 Aciclovir eye ointment 3% Zovirax®

Prescribe generically for Herpes simplex infections 

13.05.02 Acitretin Neotigason®

Dermatology initiation. NB highly teratogenic

 

03.01.04 Aclidinium and formoterol inhaler Duaklir Genuair ®
13.08.01 Actikerall ® 
01.05.03 Adalimumab 

 For hospital use only

10.01.03 Adalimumab Humira®

 In line with NICE technology appraisals and local guidance

11.04.02 Adalimumab  Humira®

 Injectable preparation not suitable for primary care prescribing

13.05.03 Adalimumab Humira®

Injectable preparation not suitable for primary care prescribing

 

A5.07 Aderma dermal pads 
08.02.02 AdoPORT ® Tacrolimus

Do not prescribe for new renal transplant patients

03.04.03 Adrenaline / epinephrine 1 in 1,000 
02.07.03 Adrenaline / Epinephrine 1 in 10,000 (dilute) 
08.02.02 Advagraf ® 

Do not prescribe for new renal transplant patients

 

03.01.05 AeroChamber Plus ® 
05.05.01 Albendazole 

 Unlicensed product 

09.02.02.02 Albumin Solution 

Note: This is obtained from Pathology, not Pharmacy

08.01.05 Alectinib Alecensa®

Oral cancer drug NHSE commissioned

06.06.02 Alendronic Acid 
09.06.04 Alfacalcidol One-Alpha®

Vitamin D prescribing guidelines are available on WVT intranet and CCG internet. Maintenance doses of vitamin D are suitable for self care / patient purchase in primary care.

15.01.04.03 Alfentanil Rapifen®
07.04.01 Alfuzosin 
07.04.01 Alfuzosin modified release
13.05.01 Alitretinoin Toctino®

 

 

10.01.04 Allopurinol 
06.01.02.03 Alogliptin Vipidia▼®

First line DPP4.

Use within NICE recommendations: continue only if HbA1c is reduced by at least 0.5%within six months of starting treatment

09.06.05 Alpha Tocopheryl Acetate 

Vitamin E suspension & capsules

07.01.01.01 Alprostadil Prostin VR®

 Restricted to Consultant Paediatrician 

07.04.05 Alprostadil Caverject®

 Restricted to initiation by the specialist urology team

07.04.05 Alprostadil MUSE®

 Restricted to initiation by the specialist urology team

07.04.05 Alprostadil 3mg/g cream Vitaros®

Restricted to initiation by the specialist urology team 

02.10.02 Alteplase Actilyse®

Acute PE

Intra-arterial Lysis

Management of acute ischaemic stroke, if within 4 ½ hours of onset of symptoms

 

09.05.02.02 Aluminium Only Preparations Alu-Cap®
01.02 Alverine citrate 

 Restricted to Gastroenterologist initiation only

04.09.01 Amantadine 

Used in dyskinetic patients

02.05.01 Ambrisentan 
10.02.01 Amifampridine Firdapse
05.01.04 Amikacin 

On consultant microbiology recommendation only, or specialist ophthalmology use

11.03.01 Amikacin 

Consultant ophthalmologist only. See endophthalmitis protocol

02.02.03 Amiloride Hydrochloride 

Alternative when first line not suitable

13.08 Aminolevulinic acid  Ameluz®
03.01.03 Aminophylline Phyllocontin Continus®

Prescribe by brand

02.03.02 Amiodarone 

Initiation should be under specialist control. Care must be taken to ensure the dose titration used is appropriate – see BNF.

 

04.02.01 Amisulpride 
04.03.01 Amitriptyline 
04.07.03 Amitriptyline 

Off-label use . Routinely used and included in NICE (CG173) guidelines

 

 

04.07.04.02 Amitriptyline 

Off label use

02.06.02 Amlodipine 
05.01.01.03 Amoxicillin 

Oral and I.V. 

Use Amoxicillin injection 1g tds instead of Ampicillin injection

3g oral sachets are available for use in Bronchiectasis in line with BTS guidelines

 

05.02 Amphotericin Fungizone®

Specialist ophthalmic use only

Contact pharmacy technical services (ext 2997) who will reconstitute individual doses

05.02 Amphotericin AmBisome®

Contact pharmacy technical services (ext 2997) who will reconstitute individual doses

09.01.04 Anagrelide Xagrid®

Haematology prescribing only  

08.03.04.01 Anastrozole 
05.02.04 Anidulafungin Ecalta®

Consultant microbiologist recommendation only

11.04.02 Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin®

Allergic conjunctivitis. Use with caution in patients susceptible to angle closure glaucoma

01.07.01 Anusol cream 

Hospital in-patients only. Soothing haemorrhoid preparations not suitable for prescription in primary care

 

01.07.01 Anusol suppositories 

Hospital in-patient use only. Soothing haemorrhoid preparations not suitable for prescription in primary care

 

02.08.02 Apixaban Eliquis®

 

 

04.09.01 Apomorphine APO-go® or Dacepton®

Sub-cut infusion or prefilled pen under direction of PD team - see shared care

Prescribe by brand as devices differ.

Dacepton® first line for new patients

13.05.03 Apremilast Otezla®

For active psoriatic arthritis in line with TA433

13.05.03 Apremilast Otezla®

For active psoriatic arthritis in line with TA433

13.02.01 Aproderm® Colloidal Oatmeal 

Equivalent formulation to Aveeno cream.

13.02.01 Aquadrate ® 10% cream 
01.06.03 Arachis Oil 

Contraindicated if hisotry of hypersensitivity to arachis oil or peanuts

04.02.01 Aripiprazole 
04.02.02 Aripiprazole Abilify Maintena®
06.02.01 Armour thyroid ® 

 Desiccated porcine thyroid gland: see Herefordshire LPT

09.06.03 Ascorbic Acid Vitamin C

Note: Restricted availability of strengths

04.07.01 Aspirin 

Prescribe as dispersible tablets

02.09 Aspirin (antiplatelet) 

Prescribe as dispersible only (can be swallowed whole). No proven value for Enteric Coated preparations.

Suppositories (unlicensed preparation) are available

 

 

02.04 Atenolol 
04.04 Atomoxetine 
02.12 Atorvastatin 
07.01.03 Atosiban 

Very expensive agent but on formulary because the Drug & Therapeutics Committee could not accept the rare but serious risks of the alternative – nifedipine capsules.

05.04.08 Atovaquone Wellvone®
15.01.05 Atracurium 
11.05 Atropine 

1% eye drop and 1% eye ointment

Action up to seven days

15.01.03 Atropine  
11.05 Atropine Sulphate single use Minims® Atropine Sulphate

Action up to seven days

10.03.02 Axsain ® 

Restricted: Consultant initiation only

A2.02.02.03 Aymes ActaGain 2.4 Complete Maxi 

200ml milkshake style supplement (ready to drink). One bottle daily - see prescribing guidelines and pathway

A2.02.01.02 AYMES Shake 

First line supplement for most patients in the community – mix with 200ml whole milk

For guidance on prescribing sip feeds in primary care see CCG oral nutritional support internet page, including prescribing guidance, Food First and Nourishing Drinks leaflets & MUST score tool. Note ACBS requirements.

A2.02.01.02 Aymes Shake Compact powder 

Mix with 100ml whole milk

A2.02.01.02 Aymes Shake Smoothie powder 

Mix with 150ml water (juice drink)

08.01.03 Azacitidine Vidaza®
01.05.03 Azathioprine 
08.02.01 Azathioprine 

 Hospital Only for NEW renal transplant patients

08.02.01 Azathioprine Imuran®
10.01.03 Azathioprine 
11.04.02 Azelastine Optilast®
05.01.05 Azithromycin 

For GUM, paediatrics and as prophylaxis in respiratory patients

05.01.02.03 Aztreonam Azactam®

For serious infections only as per Herefordshire Antibiotic Guidelines or consultant microbiologist recommendation

10.02.02 Baclofen 
13.02.01 Balneum ® Plus cream 
13.02.01 Balneum® cream 

useful where a keratolytic is required e.g. hyperkeratosis, icthyosis 

01.05.01 Balsalazide 

Specialist initiation only

10.01.03 Baricitinib Olumiant®

For moderate to severe rheumatoid arthritis in line with TA466

13.02.02 Barrier preparation Conotrane®
13.02.02 Barrier preparation Cavilon®

In line with wound care formulary and continence, stoma guidance as appropriate

08.02.04 BCG bladder instillation OncoTICE®

Specialist use only

08.02.04 BCG bladder instillation ImmuCyst®

Specialist use only

06.01.01.03 BD Viva 4mm

Prescribe by brand for cost savings and continuity – see guidance for range of needles on formulary which are universal fitting.

03.02 Beclometasone Easyhaler®
03.02 Beclometasone Clenil Modulite®
03.02 Beclometasone 

PRESCRIBE BY BRAND TO ENSURE CONSISTENCY OF SUPPLY

03.02 Beclometasone Qvar®
03.02 Beclometasone and formoterol Fostair NEXThaler®

Beclometasone dipropionate & formoterol fumarate (MDI) & NEXThaler (DPI)

NB beclometasone equivalent to QVAR® and therefore double potency BDP

First line combination in asthma for new patients and those stepping down

Consider first line in COPD where a combination ICS/LABA product is required in MDI presentation

03.02 Beclometasone and formoterol Fostair®

Beclometasone dipropionate & formoterol fumarate (MDI) & NEXThaler (DPI)

NB beclometasone equivalent to QVAR® and therefore double potency BDP

First line combination in asthma for new patients and those stepping down

Consider first line in COPD where a combination ICS/LABA product is required in MDI presentation

03.02 Beclometasone Dipropionate Clenil Modulite®
12.02.01 Beclometasone Dipropionate 

Beconase 200 dose pack in Primary Care

12.02.01 Beclometasone Dipropionate Beconase®

200 dose pack in Primary Care

03.04.02 Bee and Wasp Allergen Extracts Pharmalgen®

NICE TA 246

08.01.01 Bendamustine 
02.02.01 Bendroflumethiazide 
20 Benzoin Tincture, Compound, BP 

Purchase for self-care in Primary Care

12.03.01 Benzydamine Difflam®

Mouthwash. For self-care & over the counter (OTC) purchase in primary care 

05.01.01.01 Benzylpenicillin Crystapen®

 

No longer recommended for skin and soft tissue infections in adults

05.01.01.01 Benzylpenicillin Benzathine 

 Unlicensed preparation. 

For use in Sexual Health clinic only for treatment of syphilis 

04.06 Betahistine Dihydrochloride 

For Ménière’s disease

06.03.02 Betamethasone Betnesol®
13.04 Betamethasone (as Valerate) 0.025% Betnovate-RD®
13.04 Betamethasone (as Valerate) 0.1% Betnovate®
12.01.01 Betamethasone 0.1% with Neomycin 0.5% ear drops Betnesol N®
11.04.01 Betamethasone 0.1% with Neomycin 0.5% eye drops Betnesol N®

Combination products are rarely justified except after surgery to reduce inflammation and prevent infection.

12.01.01 Betamethasone ear drops 
13.04 Betamethasone Esters Betesil®

On specialist dermatology advice (replaces Haelan tape)

11.04.01 Betamethasone eye drops 

Short term treatment of local inflammation

11.04.01 Betamethasone eye ointment Betnesol®

Prescribe generically for short term treatment of local inflammation 

12.02.01 Betamethasone nasal drops 
12.02.01 Betamethasone Sodium Phosphate Vista-Methasone®

Prescribe generically

13.04 Betamethasone valerate 0.1% scalp application 
11.06 Betaxolol Betoptic®

Single dose preservative free 0.25% eye drops second line

(Timolol PF is temporarily unavailable from the manufacturers)

11.04.01 Bethamethasone with Neomycin Vista-Methasone-N®

Prescribe generically. Combination products are rarely justified except after surgery to reduce inflammation and prevent infection.

11.08.02 Bevacizumab intravitreal injection Avastin®

Unlicensed use for neovascular rubeotic glaucoma in Ophthalmology only.

For other indications discuss with CCG on an individual patient basis.

02.12 Bezafibrate 
A5.02.05 Biatain Adhesive 
A5.02.05 Biatain Non- Adhesive 
08.03.04.02 Bicalutamide 

Prescribe generically. Use 50mg OD for four weeks to inhibit tumour flare when starting treatment with an LHRH analogue

11.06 Bimatoprost Lumigan®

Prescribe generically

Prostaglandin analogues can cause changes in eye colouration and irritation

0.01% eye drops second line when first line prostaglandin are not tolerated

Preservative free preparations are reserved for patients with proven sensitivity to benzalkonium chloride.

Bimatoprost single dose eye drops 0.03% first line preservative free 

11.06 Bimatoprost with Timolol Ganfort®
06.01.01.02 Biphasic Insulin Aspart NovoMix® 30

3ml cartridges (Novopen®). 3ml disposable pens (Flexpen®)

06.01.01.02 Biphasic Insulin Lispro Humalog® Mix

Mix 25 and 50 - 3ml cartridges (Autopen® Classic or Humapen®), 3ml disposable pens (KwikPens®)

06.01.01.02 Biphasic Isophane Insulin Insuman® Comb

Use human isophane insulin first before analogues in Type 2 diabetes in line with NICE NG28

3ml cartridge for Clickstar® for omb 15 and 50, and also disposable pens Solostar® for Comb 25

06.01.01.02 Biphasic Isophane Insulin Humulin® M3

Use human isophane insulin first before analogues in type 2 diabetes in line with NICE NG28

3ml cartridges Humapen® Savvio disposable pens Kwikpen®

01.06.02 Bisacodyl 
02.04 Bisoprolol 
08.01.02 Bleomycin 
06.01.06 Blood Glucose Meters 

Caresens Pro and Ketosens restricted to use for newly diagnosed patients on advice of the diabetic specialist nurses who will provide the meters and advise the patient on use – see new guidance across health economy

05.03.03.02 Boceprevir Victrelis®

Specialist use only

Used in accordance with NICE Technology Appraisal TA253

08.01.05 Bortezomib Velcade®
02.05.01 Bosentan Tracleer®
04.09.03 Botulinum A toxin Dysport®

Restricted to use outlined in Herefordshire Treatment Policy

04.09.03 Botulinum A toxin Botox®

Restricted to use outlined in Herefordshire Treatment Policy

04.09.03 Botulinum B toxin NeuroBloc®

Named patient basis

Restricted to only where Botulinum A ineffective

11.06 Brimonidine Tartrate Alphagan®

Contraindicated with monoamine oxidase inhibitor (MAOI) therapy and patients on antidepressants which affect noradrenergic transmission (e.g. tricyclic antidepressants and mianserin). Allergy and irritation

11.06 Brimonidine Tartrate 0.2% with Timolol 0.5% Combigan®
11.06 Brinzolamide Azopt®

Allergy and irritation

04.08.01 Brivaracetam Briviact®

Adjunctive therapy in partial-onset seizures with or without secondary generalisation, in patients from 16 years of age with severe refractory epilepsy warranting tertiary specialist input and have tried three or more AEDs. Patient has documented intolerance to levetiracetam and is using a third line agent (perampanel, zonisamide, lacosamide, eslicarbazepine) which would be replaced by brivaracetam. MHRA cat 3 (prescribe generically).

04.09.01 Bromocriptine 

Ergot-derived dopamine-receptor agonist no longer initiated in Parkinson’s Disease 

06.07.01 Bromocriptine 
01.05.02 Budesonide 3mg MR capsules Budenofalk®

For small bowel and Ileo-caecal crohns and also in autoimmune hepatitis

01.05.02 Budesonide 3mg MR capsules Entocort®
01.05 Budesonide 9mg MR granules Budenofalk®
01.05.02 Budesonide 9mg MR tablets Cortiment®
03.02 Budesonide and formoterol DuoResp Spiromax®
03.02 Budesonide and formoterol Fobumix Easyhaler®
03.02 Budesonide and formoterol Symbicort®

Turbohaler® NB only 200/6 and 400/12 preparations are licensed in COPD

 

01.05.02 Budesonide Foam Enema Budenofalk

 First choice foam enema

 

02.02.02 Bumetanide 

1mg of oral bumetanide is equivalent to 40mg oral Furosemide

15.02 Bupivacaine and Adrenaline 
15.02 Bupivacaine Hydrochloride 
15.02 Bupivacaine Hydrochloride with Glucose Marcain Heavy®
15.02 Bupivacaine with Fentanyl 
04.07.02 Buprenorphine Temgesic®
04.07.02 Buprenorphine Butec® patch

For patients with poor swallow who are unable to tolerate higher doses of opioids.

Prescribe as BuTec. 5mcg/hr patch approx equivalent to 12mg oral morphine. 

04.10.03 Buprenorphine Subutex®

Initiated & monitored by Addaction  

04.10.03 Buprenorphine and Naloxone Suboxone®

Short term use for high risk patients in line with Addaction guidance

04.10.02 Bupropion Hydrochloride Zyban®

Not initiated in hospital

Not for FP10 prescribing. Refer all patients to Hereford council Healthy Lifestyle Trainer Service (HLTS) for behavioural support and access to pharmacotherapy. 01432 383567 healthylifestyle.trainerservice@nhs.net

06.07.02 Buserelin 

Not suitable for primary care cancer or gynaecology indications

 

08.03.04.02 Buserelin 

Not suitable for primary care, cancer or gynaecology indications

08.01.01 Busulfan 

Oral cancer drug (NHSE commissioned)

 

04.09.01 Cabergoline 

No longer initiated in Parkinsons Disease

 

06.07.01 Cabergoline 
08.01.05 Cabozantinib Cometriq®

Oral cancer drug (NHSE commissioned)

 

08.01.05 Cabozantinib Cabometyx®

Oral cancer drug (NHSE commissioned)

 

09.06.04 Cacit D3  effervescent granules sachets

An additional option for administration via PEG tubes

1.25g calcium carbonate & 440units colecalciferol per sachet

09.06.04 Calci-D®  Colecalciferol and Calcium Carbonate

First line Calcium & Vitamin D product: 1000mg Calcium [2.5g calcium carbonate] & 1000 units colecalciferol per chewable tablet.

ONE tablet ONCE daily (at 6pm to avoid morning doses of bisphosphonate and other interacting medicines eg levothyroxine)

13.05.02 Calcipotriol 50mcg/g with Betamethasone 0.05% Enstilar®

An alternative formulation to Dovobet

DO NOT add to repeat prescription in primary care – course length maximum 4 weeks which may be repeated if necessary but not for continuous use.

13.05.02 Calcipotriol 50micrograms/g with Betamethasone 0.05% 

**Contains potent steroid**

Consider step down to Calcipotriol ointment after 2-4 weeks to minimise steroid exposure.

DO NOT add to repeat prescription in primary care – course length maximum 4 weeks which may be repeated if necessary but not for continuous use.

13.05.02 Calcipotriol ointment 
06.06.01 Calcitonin (salmon) / Salcatonin 
06.06.01 Calcitonin (salmon) / Salcatonin 
09.05.02.02 Calcium Acetate Phosex®

Calcium acetate 1 g contains 250 mg / 6.2 mmol calcium per tablet

08.01 Calcium Folinate 
09.05.01.01 Calcium Gluconate 
06.01.02.03 Canagliflozin Invokana▼®

As per NICE guidance TA315

02.05.05.02 Candesartan 

 Restricted to second line agent for treatment of patients intolerant to ACE inhibitors

 

 

08.01.03 Capecitabine Xeloda®

Oral cancer drug (NHSE commissioned)

10.03.02 Capsaicin 

Restricted: Consultant initiation only

02.05.05.01 Captopril 

Captopril liquid

Unlicensed preparation for paediatrics only

 

04.08.01 Carbamazepine 

Prescribe by brand for epilepsy. Tegretol is preferred brand. MHRA cat 1.

Serum levels can be useful – narrow therapeutic index

06.02.02 Carbimazole Neo-Mercazole®

Prescribe generically

03.07 Carbocisteine 

The evidence for mucolytics is poor. Use on advice from a respiratory specialist. Review after a trial period e.g. 3 – 6 months and discontinue if no benefit.

11.08.01 Carbomers 

First line alternative to hypromellose.

Clinitas Gel (Carbomer 180 10g). Prescribe by brand in primary care / FP10 

 

11.08.01 Carbomers Viscotears®

Preservative free single use 30x0.6ml

First line alternative to hypromellose where preservative free required

Prescribe by brand in primary care / FP10

Gel - Diagnostic aid in ophthalmology (contact lens coupling agent) 

08.01.05 Carboplatin 
08.01.05 Carboplatin Paraplatin®
07.01.01 Carboprost Hemabate®
11.08.01 Carmellose 

Evolve Carmellose 0.5% PF 10ml or Celluvisc® 1% carmellose 1% single dose UDV

Second line alternative if hypromellose & carbomer ineffective. Prescribe by brand in primary care / FP10

Evolve carmellose PF have a 90 day expiry from first opening and are preservative free.

Reserve single use unit dose preparations for patients who do not experience relief with Evolve carmellose 0.5 PF%

12.03.01 Carmellose Sodium Orabase®
08.01.01 Carmustine 

Oral cancer drug commissioned by NHSE

02.04 Carvedilol 
07.04.04 Catheter Patency Solutions 
07.04.04 Catheter Patency Solutions 

Optiflo S is brand of choice

07.04.04 Catheter Patency Solutions 

Optiflo G is brand of choice

07.04.04 Catheter Patency Solutions 

Optiflo R is brand of choice

05.01.02.01 Cefalexin 

 Not recommended by microbiology – limited use in paediatric UTI

05.01.02.01 Cefotaxime 

Paediatrics only otherwise consultant microbiologist recommendation only

05.01.02.01 Ceftazidime 

Paediatrics only

11.03.01 Ceftazidime  

Consultant ophthalmologist only. See endophthalmitis protocol

05.01.02.03 Ceftazidime/ avibactam Zavicefta®

For carbapenemase-producing enterobacteriaceae (CPE) infections – microbiologist recommendation only

05.01.02.01 Ceftolozane 1g with Tazobactam 500mg Zerbaxa®

Microbiologist recommendation only

05.01.02 Ceftriaxone 

Meningitis or meningococcal septicaemia or cerebral abscess only as per guidelines

Sexual health. See BASHH guidelines for gonorrhoea

May be used for IVOPAT.

05.01.02.01 Ceftriaxone 

Injectable preparation not suitable for primary care prescribing Refer to sexual health

11.03.01 Cefuroxime  

Unlicensed use. (Aprokan) Ophthalmology theatre consultant use only. For prophylaxis of post-operative endophthalmitis in cataract surgery 

10.01.01 Celecoxib Celebrex®

Prescribe generically. See current guidance about the use of COX2 inhibitors. Please remember that COX2 inhibitors should not be used in patients with cardiovascular disease.

02.04 Celiprolol Hydrochloride 

Cardiology specialists only – SPECIAL ORDER

 

08.01.05 Ceritinib Zykadia

Oral cancer drug (NHSE commissioned)

 

10.01.03 Certolizumab Pegol Cimzia®

 In line with NICE technology appraisals and local guidance

03.04.01 Cetirizine 

Self Care for minor self-limiting conditions and Hayfever

Licensed adult dose 10mg OD however doses up to four times a day on specialist advice may be recommended eg in complex urticaria

13.02.01 Cetraben® Lotion 
04.01.01 Chloral Hydrate 500mg in 5mL 

UNLICENSED! Hospital use only. 

For sedation for painless procedures in paediatrics 

 

 

08.01.01 Chlorambucil 

Oral cancer drug (NHSE commissioned)

 

05.01.07 Chloramphenicol 

I.V. preparation. Suspected or proven meningitis with severe penicillin allergy only

11.03.01 Chloramphenicol 

0.5% eye drops, 0.5% single use minims, 1% eye ointment

First line for superficial eye infections 

04.01.02 Chlordiazepoxide 

For alcohol detoxification

12.02.03 Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin®
05.04.01 Chloroquine 

First line for treatment of benign malaria (Plasmodium vivax, P Ovale, P malariae)

10.01.03 Chloroquine 
03.04.01 Chlorphenamine 

Self Care for minor self-limiting conditions and Hayfever.

04.02.01 Chlorpromazine 
06.05.01 Choriogonadotropin Alfa Ovitrelle®

Restricted to specialist consultant initiation only

06.05.01 Chorionic Gonadotrophin Choragon®

Injectable preparation not suitable for primary care prescribing

06.05.01 Chorionic Gonadotrophin Pregnyl®

Injectable preparation not suitable for primary care prescribing

 

01.05.03 Ciclosporin 

See specialist information

08.02.02 Ciclosporin Capsorin®

Hospital only for NEW renal transplant patients

See specialist information for other indications.

Prescribe by brand to ensure consistency of supply

08.02.02 Ciclosporin Deximune®

Hospital only for NEW renal transplant patients 

See specialist information for other indications.

Prescribe by brand to ensure consistency of supply

08.02.02 Ciclosporin 

Hospital only for NEW renal transplant patients

08.02.02 Ciclosporin Sandimmun®

Hospital only for NEW renal transplant patients

See specialist information for other indications.

Prescribe by brand to ensure consistency of supply

 

10.01.03 Ciclosporin 

Restricted: Consultant initiation only.

Hospital Only for new renal transplant patients

Prescribe by brand to ensure bioequivalence.

11.99.99.99 Ciclosporin 

For atopic keratoconjunctivitis sicca (dry eye) when conventional therapies have failed

0.1% drops (Ikervis): initiated by ophthalmology - AMBER

Ointment: Unlicensed. Not suitable for Primary Care prescribing - RED

 

13.05.03 Ciclosporin 

See specialist information

01.03.01 Cimetidine 
09.05.01.02 Cinacalcet Mimpara®

Primary hyperparathyroidism – NHSE funded, not for primary care - RED

Secondary hyperparathyroidism – specialist initiated - AMBER

 

04.06 Cinnarizine 

Motion sickness, vertigo

05.01.12 Ciprofloxacin 

The widespread use of quinolones is a risk factor for C. difficile and thus the use of these agents is restricted.

Oral and I.V. preparations as per Herefordshire Antibiotic Guidelines

Ciprofloxacin has a very good bioavailability. Comparable tissue levels can be obtained by both oral and IV routes. If the patient is able to take oral medication, the IV form should be replaced by the oral tablets. 400mg twice daily IV = 750mg twice daily orally. 200mg twice daily IV = 500mg twice daily orally.

11.03.01 Ciprofloxacin 

Restricted: Consultant use only. Effective in infections caused by Pseudomonas aeruginosa. Licensed for corneal ulcers.

 Used off-label for otitis externa

08.01.05 Cisplatin 
04.03.03 Citalopram 
01.06.05 Citramag ® 

2nd line to Picolax

08.01.03 Cladribine 

 Consultant haematologist use only. For hairy cell leukaemia

05.01.05 Clarithromycin 

Oral and I.V.

As per Herefordshire Antibiotic Guidelines

05.01.06 Clindamycin 

As per Herefordshire Antibiotic Guidelines

07.02.02 Clindamycin Dalacin®
05.01.06 Clindamycin 150mg Capsules 

As per Herefordshire Antibiotic Guidelines

04.08.01 Clobazam 

 Tablets, oral suspension

In Line With NICE CG137 (Replaces TA76 and TA79)
Specialist recommendation(adults) or initiation(children)

MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history 

"SLS" in primary care – epilepsy only

13.04 Clobetasol Propionate 0.05% Dermovate®
13.04 Clobetasone Butyrate 0.05% Eumovate®
05.01.10 Clofazimine 

For leprosy NHSE commissioned

 

06.05.01 Clomifene Citrate 
06.05.01 Clomifene Citrate Clomid®
04.03.01 Clomipramine 
04.08.02 Clonazepam 

 In Line With NICE CG137 (Replaces TA76 and TA79)

For specialist recommendation (Adults) or initiation (Children)
MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

02.05.02 Clonidine 
02.09 Clopidogrel 

Clopidogrel should be stopped 1 year after a NSTEMI when used in combination with aspirin

 

07.02.02 Clotrimazole 
12.01.01 Clotrimazole 
04.02.01 Clozapine 

 

Not suitable for primary care prescribing: complex monitoring required

13.05.02 Coal tar lotion 5% Exorex®
02.02.04 Co-amilozide 

No longer recommended: occasional use only if problems with hypokalaemia, monitor carefully

05.01.01.03 Co-Amoxiclav 

Oral and I.V.

See CSM warning re: cholestatic jaundice. Recommended first line for animal bites and in specific areas in the antibiotic guidelines e.g respiratory and urinary infections. The injection should not be used as an alternative to triple therapy for intra-abdominal sepsis

04.09.01 Co-Beneldopa Madopar®CR

Prescribe by brand as Madopar

Caution with selecting correct product to prescribe, dispense, administer

04.09.01 Co-Beneldopa Madopar®

Prescribe by brand as Madopar

Caution with selecting correct product to prescribe, dispense, administer

04.09.01 Co-Careldopa Sinemet® CR

Prescribe by brand as Sinemet

Caution with selecting correct product to prescribe, dispense, administer

04.09.01 Co-Careldopa Sinemet®

Prescribe by brand as Sinemet

Caution with selecting correct product to prescribe, dispense, administer

04.09.01 Co-Careldopa Half Sinemet ®CR

Prescribe by brand as Sinemet

Caution with selecting correct product to prescribe, dispense, administer

04.09.01 Co-Careldopa and Entacapone 

Prescribe as brand Sastravi® to ensure continuity for patients

01.06.02 Co-danthramer 

For use in terminally ill patients only

01.04.02 Codeine 
04.07.02 Codeine 

Codeine-containing medicines should only be used in children over 12 years old to treat acute (short lived) moderate pain, and only if it cannot be relieved by other painkillers such as paracetamol or ibuprofen. Contra-indicated in any patient under 18 years old who undergoes the removal of tonsils or adenoids for the treatment of sleep apnoea. Not recommended in 12-18 yr olds with breathing problems.

MHRA advice April 2015 and July 2013 on use in children and adolescents.

Known to be misused and subject to drug seeking behaviour.

03.09.01 Codeine Linctus BP 

Purchase for self-care in Primary Care

10.01.04 Colchicine 
09.06.04 Colecalciferol 1,000 units Sunvit D3®

Vitamin D prescribing guidelines are available on WVT intranet and CCG internet. Maintenance doses of vitamin D are suitable for self care / patient purchase in primary care.

09.06.04 Colecalciferol 10,000units/ml drops Thorens®

200 units per drop

Vitamin D prescribing guidelines are available on WVT intranet and CCG internet. Maintenance doses of vitamin D are suitable for self care / patient purchase in primary care.

09.06.04 Colecalciferol 2,400 units/ml drops Invita D3® oral drops

Vitamin D prescribing guidelines are available on WVT intranet and CCG internet. Maintenance doses of vitamin D are suitable for self care / patient purchase in primary care.

09.06.04 Colecalciferol 25,000 unit liquid Invita D3®

Vitamin D prescribing guidelines are available on WVT intranet and CCG internet. Maintenance doses of vitamin D are suitable for self care / patient purchase in primary care.

09.06.04 Colecalciferol 800 units 

Vitamin D prescribing guidelines are available on WVT intranet and CCG internet. Maintenance doses of vitamin D are suitable for self care / patient purchase in primary care.

09.06.04 Colecalciferol 800 units Desunin®

Vitamin D prescribing guidelines are available on WVT intranet and CCG internet. Maintenance doses of vitamin D are suitable for self care / patient purchase in primary care.

09.06.04 Colecalciferol and Calcium Carbonate Calcichew-D3® Forte

For those patients who have swallowing difficulties

02.12 Colesevelam Cholestagel®

(unlicensed indication) Approved for gastroenterology use only.

For hyperbilirubinaemia, as a second line option where colestyramine is not tolerated

 

02.12 Colestyramine 
01.09.02 Colestyramine powder 
05.01.07 Colistimethate 

Shared care for pseudomonas infection in bronchiectasis. Respiratory team initiation - AMBER

DO NOT prescribe for NEW CF patients. NHSE commissioned - RED

05.01.07 Colistimethate for nebulisation Colomycin®

Shared care for pseudomonas infection in bronchiectasis. Respiratory team initiation - AMBER

DO NOT prescribe for NEW CF patients. NHSE commissioned - RED

10.03.01 Collagenase Xiapex®

Clostridium histolyticum 900 micrograms with solvent

▼For intralesional injection by trained specialists to treat Dupuytrens contracture in patients with a palpable cord.

01.01.01 Co-magaldrox Maalox®

Low sodium option

01.01.01 Co-magaldrox Mucogel®

Low sodium option

06.04.01.01 Combined continuous HRT tablet Kliofem, Kliovance, Femoston Conti, Premique

Kliovance is Formulary

06.04.01.01 Combined cyclical HRT tablet Elleste-Duet®, Femoston, Prempak-C

Elleste Duet is Formulary

07.03.01 Combined Hormonal Contraceptives Loestrin 30®
07.03.01 Combined Hormonal Contraceptives TriNovum®
09.02.02.01 Compound Sodium Lactate Intravenous Infusion 
01.04.02 Co-Phenotrope Lomotil®

Generic prescribing only

05.01.08 Co-trimoxazole 

I.V. and oral preparations.

Pneumocystis jirovecii (carinii) treatment and prophylaxis only or consultant microbiologist recommendation

This includes prophylaxis for adult and paediatric patients receiving chemotherapy

As per CSM guidance:- use in acute exacerbations of COPD and UTI is restricted to occasions where there is good bacteriological evidence of sensitivity to co-trimoxazole and good reason to prefer this combination to a single agent.

13.03 Crotamiton 10% Eurax®

May be recommended for control of itch; short term use advise patients to purchase OTC

04.06 Cyclizine 
11.05 Cyclopentolate  

Cyclopentolate eye drops 0.5% and 1%

Action up to 24 hours

11.05 Cyclopentolate Hydrochloride single use Minims® Cyclopentolate Hydrochloride

Action up to 24 hours

08.01.01 Cyclophosphamide 

Oral cancer drug commissioned by NHSE

Amber shared care status if rheumatology

10.01.03 Cyclophosphamide 

Immunosuppressant in Rheumatology - AMBER

 

03.04.01 Cyproheptadine Periactin®

Hospital only for emergency treatment of SSRI poisoning  

08.03.04.02 Cyproterone 

(Acetate) 50-100mg TDS for hot flushes only (not to be used to reduce tumour flare)

06.04.02 Cyproterone Acetate 
08.01.03 Cytarabine 
02.08.02 Dabigatran Pradaxa®
08.01.05 Dacarbazine 
08.01.02 Dactinomycin Cosmegen Lyovac®
02.08.01 Dalteparin Fragmin®

For oncology use in line with Gloucestershire formulary

06.07.02 Danazol 
10.02.02 Dantrolene 
01.06.02 Dantron 

In combination with poloxamer 118 (co-danthramer).

For use in terminally ill patients only

06.01.02.03 Dapagliflozin Forxiga▼®

**Care with Dosing**

10mg OD licensed for T2DM

5mg OD licensed for T1DM

05.01.10 Dapsone 

Dermatology use for dermatitis herpetiformis

05.01.07 Daptomycin Cubicin®

Consultant microbiology recommendation only. For complex MRSA bacteraemia where vancomycin MIC exceeds 2mg/ml and/or failure to respond to vancomycin or linezolid 

05.01.07 Daptomycin Cubicin®

Consultant microbiology recommendation only. For complex MRSA bacteraemia where vancomycin MIC exceeds 2mg/ml and/or failure to respond to vancomycin or linezolid 

09.01.03 Darbepoetin Alfa Aranesp®

Not suitable for primary care prescribing due to complex commissioning arrangements  

07.04.02 Darifenacin Emselex®
08.01.05 Dasatinib Sprycel®

Oral cancer drug (NHSE commissioned)

 

08.01.02 Daunorubicin 
A5.07 Debrisoft 
09.01.03 Deferasirox Exjade®
08.03.04.02 Degarelix Firmagon®

▼ Consultant initiation only in advanced hormone dependant Prostate cancer - see shared care

 

06.06.02 Denosumab Prolia®

2nd line agent where a bisphosphonate cannot be tolerated or compliance is an issue in line with NICE – see shared care

13.02.01 Dermatonics Once Heel Balm ® 

Specialist initiation only for plantar psoriasis with deep fissures where there is a risk of cellulitis developing. Self purchase (OTC) for other indications

13.02.01 Dermol ® Cream 

Contains antimicrobial

13.02.01 Dermol® Lotion 

Contains antimicrobial

09.01.03 Desferrioxamine Mesilate Desferal®

Complex therapy not suitable for primary care prescribing  

06.05.02 Desmopressin 

Desmotabs and Desmospray

06.05.02 Desmopressin Desmotabs®
06.05.02 Desmopressin Desmospray®
07.03.02.01 Desogestrel Cerazette®, Cerelle®

Prescribe generically in Primary Care

06.03.02 Dexamethasone 
11.04.01 Dexamethasone eye drops Maxidex®

Short term treatment of local inflammation

11.04.01 Dexamethasone eye drops single use 
11.04.01 Dexamethasone intravitreal implant Ozurdex®

Ophthalmology Consultant use in macular oedema NICE TA229

12.01.01 Dexamethasone with Antibacterials (ear) Sofradex®
11.04.01 Dexamethasone with Antibacterials (eye) Sofradex®

Combination products are rarely justified except after surgery to reduce inflammation and prevent infection

11.04.01 Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol®

Combination products are rarely justified except after surgery to reduce inflammation and prevent infection

04.04 Dexamfetamine 

Not suitable for primary care prescribing.

 

04.07.02 Diamorphine Hydrochloride Injection 
04.01.02 Diazepam 

First choice for short term use in anxiety disorders.

DO NOT prescribe 10mg tablets - subject to misuse

04.08.02 Diazepam epilepsy

Rectal 1st line for status epilepticus

10.02.02 Diazepam 

Diazepam should not routinely be added to NSAIDs for the treatment of acute lower back pain.

10mg tablets should NOT be prescribed (make up the dose with 2mg and 5mg)

15.01.04.01 Diazepam 
06.01.04 Diazoxide 

For use in intractable hypoglycaemia. Will be purchased on an individual patient basis

10.01.01 Diclofenac 

Restricted: oral preparation not recommended for routine use. Please note: IM injection – maximum of 4 doses in 48 hours – see data sheet. Voltarol dispersible tablets are for patients who cannot swallow tablets.

See MHRA warning January 2015 and updated contra-indications – tablets not for new patients

11.08.02 Diclofenac Voltarol® Ophtha

Single use drops

13.08.01 Diclofenac Solaraze®
10.01.01 Diclofenac with Misoprostol Arthrotec 50 and 75®

Not recommended for new patients

Restricted: Second line agent in patients with criteria to support the use of Misoprostol

01.02 Dicycloverine 
08.03.01 Diethylstilbestrol 
02.01.01 Digoxin 

Ensure that the dose is clearly written in MICROGRAMS.

Serum digoxin levels are recommended as a support for clinical evaluation.

Steady state levels are achieved in 7–10 days. Levels should be taken 6–24 hours post dose.

 

02.01.01 Digoxin specific antibody fragments Digifab®

 For use in cardiac glycoside overdose when measures beyond simple supportive measures are not considered sufficient

04.07.02 Dihydrocodeine 

Known to be misused and subject to drug seeking behaviour.

05.04.02 Diloxanide 

Specialist use only. Not stocked in WVT pharmacy. Purchased when needed . 

01.07.04 Diltiazem Cream 2% 

This is an unlicensed preparation. Prescribe by brand in primary care (Anoheal® or Neozem®) – see specials guidance

02.06.02 Diltiazem Hydrochloride 

Please prescribe as Zemtard

At 360mg dose, please use Viazem XL

08.02.04 Dimethyl fumarate Tecfidera®

Not suitable for primary care prescribing

 

07.01.01 Dinoprostone Prostin E2®

 Vaginal tablets only. Restricted: Consultant use only

07.01.01 Dinoprostone Propess®

Vaginal tablets. To be available as option for induction of labour at term 

02.03.02 Disopyramide 
07.04.01 Distigmine Bromide 
04.10.01 Disulfiram Antabuse®

Initiated by Addaction in line with their treatment guidelines

13.05.02 Dithranol Dithrocream®
02.07.01 Dobutamine 
08.01.05 Docetaxel Taxotere®
01.06.02 Docusate Sodium 
04.06 Domperidone 
04.11 Donepezil 

Orodispersible tablets reserved for use in swallowing difficulties.

See Dementia shared care for more information. May be recommended for initiation by community dementa nurses.

02.07.01 Dopamine 
02.07.01 Dopamine Hydrochloride Select-A-jet® Dopamine
03.07 Dornase Alfa Pulmozyme®

Do not prescribe for new CF patients: NHSE commissioned  

11.06 Dorzolomide 2% with Timolol 0.5% Cosopt®
13.02.01 DoubleBase Dayleve ® 
03.05.01 Doxapram Dopram®
  • Infusion 1g in 500ml
  • Injection 100mg in 5ml

 

15.01.07 Doxapram Dopram®
02.05.04 Doxazosin 

Prescribe standard release only

No evidence of benefit of modified release over standard release doxazosin – Low Value Medicine

 

07.04.01 Doxazosin 

Standard release only

Modified release (XL) preparations do not confer any significant advantage – Low Value Medicine

08.01.02 Doxorubicin 
08.01.02 Doxorubicin Caelyx®
05.01.03 Doxycycline 

May be an option in MRSA infection. Also may be used as an adjunct to quinine in treatment of Falciparum malaria.

A5.07.01 Dressit 
02.03.02 Dronedarone Multaq®

As per NICE guideline TA197

Note safety alert regarding hepatic and cardiac side effects

 

06.01.02.03 Dulaglutide Trulicity®

Initiated by diabetes specialist only, in line with NICE guidance.

Continue only if a beneficial metabolic response (at least 1 percentage point HbA1c reduction and a weight loss of 3% within 6 months of starting treatment occurs and is maintained

Accepted onto formulary (Apr 2016) as a once weekly preparation in line with NICE NG28 type 2 diabetes guidance for patients who:

•have a BMI of 35 kg/m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or

•have a BMI lower than 35 kg/m2 and:

◦for whom insulin therapy would have significant occupational implications or

◦weight loss would benefit other significant obesity-related comorbidities. [new 2015]

 

04.07.03 Duloxetine 
06.04.01.02 Dydrogesterone Duphaston®
06.04.01.02 Dydrogesterone Duphaston® HRT
02.08.02 Edoxaban Lixiana®

1st line choice for new AF patients

 

10.02.01 Edrophonium Chloride 

Unlicensed product.

Restricted for the diagnosis of myasthenia gravis.

09.01.04 Eltrombopag Revolade®

Not suitable for primary care prescribing  

01.04.02 Eluxadoline Truberzi®

Specialist initiation (IBS) in line with NICE TA471

 

13.02.01 Emollin ® Spray 

For very painful / fragile skin where "hands on" application of creams or ointments is difficult

06.01.02.03 Empagliflozin Jardiance▼®

As per NICE TA336

02.05.05.01 Enalapril  

For postpartum hypertension when first choice agents cannot be used or cardiac/renal protection needed.

 

02.08.01 Enoxaparin 

Prescribe by brand Clexane or as biosimilar Inhixa

A2.02.02.01 Ensure ® Plus Milkshake style 

only use when first line supplements are not suitable or via PEG

A2.02.02.01 Ensure ® Plus Yoghurt style 

only use when first line supplements are not suitable or via PEG

A2.02.01.02 Ensure® Shake 

First line supplement for most patients in the community – mix with 200ml whole milk

For guidance on prescribing sip feeds in primary care see CCG oral nutritional support internet page, including prescribing guidance, Food First and Nourishing Drinks leaflets & MUST score tool. Note ACBS requirements.

04.09.01 Entacapone Comtess®

COMT inhibitor

05.03.03.01 Entecavir Baraclude®

Specialist use only

Supplied via "Homecare". Used in accordance with NICE Technology Appraisal TA153

08.02.02 Envarsus® 

Do not prescribe for new renal transplant patients

 

08.03.04.02 Enzalutamide Xtandi®

Oral cancer drug (NHSE commissioned)

 

02.07.02 Ephedrine 
12.02.02 Ephedrine 

For self-care & over the counter (OTC) purchase in primary care

13.02.01 Epimax ® Cream 
13.02.01 Epimax Oatmeal 

Equivalent formulation to Aveeno cream.

13.02.01 Epimax Ointment 
13.02.01 Epimax Paraffin-Free Ointment 

Only for patients who continue to smoke

08.01.02 Epirubicin 
02.02.03 Eplerenone 

Second line to spironolactone

 

09.01.03 Epoetin alfa Eprex®

Not suitable for primary care prescribing due to complex commissioning arrangements

09.01.03 Epoetin beta NeoRecormon®

Not suitable for primary care prescribing due to complex commissioning arrangements  

09.01.03 Epoetin Theta Eporatio®

Not suitable for primary care prescribing due to complex commissioning arrangements  

02.08.01 Epoprostenol Flolan®

Restricted to ITU use

 

02.09 Eptifibatide Integrilin®
09.06.04 Ergocalciferol 

Hospital use only for patients with high output stoma / severe malabsorption.

07.01.01 Ergometrine Maleate 
07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®
08.01.05 Erlotinib Tarceva®

Oral cancer drug (NHSE commissioned)

 

08.01.05 Erlotinib Tarceva®

Oral cancer drug (NHSE commissioned)

 

05.01.02.02 Ertapenem Invanz®

For serious infections only as per Herefordshire Antibiotic Guidelines or consultant microbiologist recommendation only.

May be used for IVOPAT

May be used first line if there is a history of infection with ESBL

 

06.01.02.03 Ertugliflozin 

As an option in line with NICE guidance

https://www.nice.org.uk/guidance/ta572

https://www.nice.org.uk/guidance/ta583

05.01.05 Erythromycin 

Oral

May be used IV as a prokinetic in ICU, and surgery

04.03.03 Escitalopram Cipralex®

2nd line

04.08.01 Eslicarbazepine Zebinix®

MHRA cat 2

02.04 Esmolol 

Cardiology specialists only. Available on CCU

 

01.03.05 Esomeprazole 
08.01.01 Estramustine Phosphate Estracyt®

Oral cancer drug (NHSE commissioned)

 

02.11 Etamsylate Dicynene®

Prescribe generically

10.01.03 Etanercept Benepali®

  In line with NICE technology appraisals and local guidance

10.01.03 Etanercept Erelzi®

 In line with NICE technology appraisals and local guidance

10.01.03 Etanercept Enbrel®

 In line with NICE technology appraisals and local guidance

13.05.03 Etanercept Enbrel®

Injectable preparation not suitable for primary care prescribing

09.05.01.02 Etelcalcetide Parsabiv®

Injectable preparation not suitable for primary care prescribing  

05.01.09 Ethambutol  

All prescribing should be consistent with national guidelines, or under the advice of specialist chest physicians or consultant microbiologists

02.13 Ethanolamine Oleate 
07.03.01 Ethinylestradiol 20mcg / desogestrel 150mcg Gedarel®, Mercilon®

Gedarel 1st line brand of choice

07.03.01 Ethinylestradiol 20mcg / gestodene 75 mcg Millinette®, Femodette®, Juliperla®

Millinette 1st line brand of choice

07.03.01 Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel®, Marvelon®

Gedarel 1st line brand of choice

07.03.01 Ethinylestradiol 30mcg / gestodene 75 mcg Millinette®, Femodene®,Sofiperla®

Millinette 1st line brand of choice

07.03.01 Ethinylestradiol 30mcg / levonorgestrel 150mcg Rigevidon®, Microgynon 30®, Levest®

Rigevidon 1st line brand of choice

07.03.01 Ethinylestradiol 35 mcg / noresthisterone 1mg Norimin®
07.03.01 Ethinylestradiol 35 mcg / noresthisterone 500mcg Ovysmen®, Brevinor®

Brevinor 1st line brand of choice

07.03.01 Ethinylestradiol 35 mcg / norgestimate 250 mcg Cilique®
04.08.01 Ethosuximide 

MHRA cat 3 (prescribe generically)

10.01.01 Etodolac 

Note: Second line agent only

15.01.01 Etomidate Etomidate-Lipuro®
07.03.02.02 Etonorgestrel Implanon®
08.01.04 Etoposide 

 Vinca alkaloids must never be given intrathecally. This is extremely dangerous! 

13.02.01 ExCetra® Cream 

Equivalent formulation to Cetraben cream

06.01.02.03 Exenatide Byetta▼®

Initiated by diabetes specialist only, in line with NICE guidance.

Continue only if a beneficial metabolic response (at least 1 percentage point HbA1c reduction and a weight loss of 3% within 6 months of starting treatment occurs and is maintained

NICE recommendation: Consider adding exenatide to metformin and a sulphonylurea if:

 BMI > 35kg/m2 in those of European descent with adjustment for other ethnic groups, and specific psychological or medical problems associated with high body weight

 A BMI > 35kg/m2 and for whom initiation of insulin therapy would have significant occupational implications, or where weight loss would benefit other significant comorbidities

06.01.02.03 Exenatide prolonged release Bydureon▼®

Initiated by diabetes specialist only, in line with NICE guidance.

Continue only if a beneficial metabolic response (at least 1 percentage point HbA1c reduction and a weight loss of 3% within 6 months of starting treatment occurs and is maintained

Once weekly preparation NICE TA248

Consider adding prolonged-release exenatide to metformin and either a sulphonylurea or a thiazolidinedione if blood glucose levels are not under control, and:

 BMI of 35 or above and have health problems associated with this, or

 BMI of less than 35, and treatment with insulin would make it much more difficult to maintain lifestyle or other significant health problems would be helped by weight loss

 Prolonged-release exenatide can be given with one other drug (metformin or a sulphonylurea) only if:

 patient is not able to take either metformin or a sulphonylurea, and

 patient is not able to take thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors

02.12 Ezetimibe Ezetrol®

Second line option when statins not tolerated. Prescribe generically.

 

08.02.04 Fampridine 

Not suitable for primary care prescribing

 

10.01.04 Febuxostat Adenuric®

Febuxostat is recommended as an option for the management of chronic hyperuricaemia in gout only for people who are intolerant of allopurinol or for whom allopurinol is contraindicated in line with NICE TA164.

02.06.02 Felodipine 

2nd line after Amlodipine

04.07.02 Fentanyl Matrifen

Prescribe by brand as good practice to ensure consistency of supply.

MATRIFEN is HCCG brand of choice

15.01.04.03 Fentanyl 
04.07.02 Fentanyl Nasal Spray PecFent®

Second line use by the Palliative Care team for incident pain only. Not for routine use for breakthrough pain with fentanyl patches. 

04.07.02 Fentanyl sublingual tablets Abstral®

Second line use by the Palliative Care team for incident pain only. Not for routine use for breakthrough pain with fentanyl patches. 

09.01.01.02 Ferric Carboxymaltose Ferinject®

Injectable preparation not suitable for primary care prescribing  

09.01.01.01 Ferrous Fumarate Fersamal® Syrup
09.01.01.01 Ferrous Fumarate 
09.01.01.01 Ferrous Gluconate 
09.01.01.01 Ferrous Sulphate 
03.04.01 Fexofenadine 

3rd line non-sedating option, particularly for urticaria. Prescribe generically.

 

05.01.07 Fidaxomicin Dificlir®

Consultant microbiologist or gastroenterologist recommendation only.

For C difficile refractory to metronidazole and vancomycin and for those at high risk of a relapse as per public health advice

 

09.01.06 Filgrastim Ratiograstim®

Injectable preparation not suitable for primary care prescribing   

09.01.06 Filgrastim Nivestim®

Injectable preparation not suitable for primary care prescribing  

09.01.06 Filgrastim Neupogen®

Injectable preparation not suitable for primary care prescribing  

09.01.06 Filgrastim Zarzio®, Accofil®

Injectable preparation not suitable for primary care prescribing  

06.04.02 Finasteride 
02.03.02 Flecainide 
13.04 Flucinolone Acetonide 0.025% Synalar® gel

Off label use by ENT recommendation for severe inflammatory oral conditions such as lichen planus and severe mouth ulcers

13.04 Flucinolone Acetonide 0.025% with Neomycin Sulphate 0.5% Synalar N®
05.01.01.02 Flucloxacillin 

Oral and I.V.

Use at a dose of 2g IV qds for skin and soft tissue infections (ISS B and C)

05.02 Fluconazole 

Oral and I.V. preparations

Caution: check for drug interactions

 

07.02.02 Fluconazole 
08.01.03 Fludarabine Phosphate Fludara®
06.03.01 Fludrocortisone 
15.01.07 Flumazenil Anexate®
12.01.01 Flumetasone 0.02% with Clioquinol 1% Locorten-Vioform®
11.08.02 Fluorescein Sodium 

Minims

11.04.01 Fluorometholone FML®

Useful when prednisolone 0.5% is not available

08.01.03 Fluorouracil 
13.08.01 Fluorouracil Efudix®
04.03.03 Fluoxetine 

Long half life may be beneficial in patients with adherence issues

04.02.02 Flupentixol Decanoate 
08.03.04.02 Flutamide 

Oral cancer drug (NHSE commissioned

 

12.02.01 Fluticasone + Azelastine Dymista

Second line – see BSACI rhinitis guidelines

03.02 Fluticasone furoate & vilanterol Relvar Ellipta®

Relvar Ellipta 92/22® fluticasone furoate & vilanterol 92/22 low strength: for asthma and COPD in line with NICE & BTS guidance.

Relvar Ellipta 184/22® fluticasone furoate & vilanterol 184/22 high strength: for asthma in line with NICE & BTS guidance

12.02.01 Fluticasone Propionate 

For nasal polyps only 

12.02.01 Fluticasone Propionate Flixonase Nasule®

For nasal polyps only 

03.02 Fluticasone propionate and formoterol Flutiform®

2nd line agent.

NB: MDI is licensed in asthma only

03.02 Fluticasone propionate and salmeterol AirFluSal Forspiro®

Do not start for new COPD patients

 

03.02 Fluticasone propionate and salmeterol Sirdupla®, Seretide®, Airflusal®

Do not start for new COPD patients

AirFluSal is HCCG preferred brand

NB Only 500 Accuhaler® licensed in COPD

 

20 Flutter Device

Supplied under the direction of a respiratory physiotherapist or other specialist respiratory clinician in secondary care and not issued on FP10 in primary care.

 

In line with the BTS guidelines for non-cystic bronchiectasis oscillation devices may be prescribed for use with postural drainage and forced expiration when helping people develop effective mucus clearance techniques. BTS guidelines

 

09.01.02 Folic Acid 

400mcg tablets considered to be self care

02.08.01 Fondaparinux Arixtra®

Injectable preparation not suitable for primary care prescribing

For prophylaxis of VTE in line with NICE NG89 as an alternative if LMWH is contra-indicated or if a non-animal derived product is requested

 

A2.02.01.02 Foodlink® Complete with Fibre  

mix with 200ml whole milk

20 Formaldehyde 5% solution 

 UNLICENSED PRODUCT – for radiation proctitis.

 

20 Formaldehyde rectal solution 

 UNLICENSED PRODUCT – for radiation proctitis.

 

03.01.01.01 Formoterol  

1st line long acting Beta 2 agonist (LABA)

Easyhaler £

MDI Atimos Modulite ££

Turbohaler Oxis ££

 

 

 

03.02 Formoterol fumarate, beclometasone dipropionate and glycopyrronium bromide  
A2.02.02.01 Fortisip ® Bottle 

only use when first line supplements are not suitable or via PEG

05.01.07 Fosfomycin 

Use on advice of a microbiologist only – supply via hospital on GP FP10 (see guidelines).

 

13.05.02 Fumaderm ®  

Unlicensed: not suitable for primary care prescribing

 

02.02.02 Furosemide 

Absorption improved if taken before food

11.03.01 Fusidic Acid 

Fucithalmic® Useful for staphylococcal infections

04.07.03 Gabapentin 

Titrate slowly - see guidance

04.08.01 Gabapentin 

MHRA cat 3 (prescribe generically)

04.11 Galantamine 

Tablets and liquid. Liquid reserved for use in swallowing difficulties 

Prescribe MR as Gatalin XL.

Dementia - see shared care. May be recommended for initiation by community dementa nurses.

05.03.02.02 Ganciclovir Cymevene®

Specialist use only

08.01.05 Gefitinib Iressa®

Oral cancer drug (NHSE commissioned)

09.02.02.02 Gelatin Gelaspan®

Gelaspan® (balanced gelofusine) This will replace some tetraspan use

08.01.03 Gemcitabine Gemzar®

Prescribing note: Use according to NICE guidance

05.01.04 Gentamicin 

As per Herefordshire Antibiotic Guidelines

Dosing should usually be based on 7mg/kg once daily, calculated using the Hartford nomogram, available as a gentamicin calculator on the intranet.

 

Levels should be taken 6-13 hours after the dose and re-entered into the calculator to confirm an appropriate dosage interval

The Hartford dosage schedule is not appropriate for soft tissue infections or bacterial endocarditis, Please see the Trust guidelines on the intranet link as above

Adult prophylactic doses should be 2mg/kg to a maximum of 240mg rounded to the nearest 20mg

For paediatric use please see local guidelines on intranet

For neonatal use please see departmental guidelines.

 

11.03.01 Gentamicin ophthalmic

Gentamicin Sulphate 0.3% & 1.5% eye drops Preservative free eye drops 1.5%

 Effective for infections caused by Pseudomonas aeruginosa

11.03.01 Gentamicin single use Minims® Gentamicin Sulphate

Effective for infections caused by Pseudomonas aeruginosa

08.02.04 Glatiramer Acetate Copaxone®

Injectable preparation (NHSE commissioned)

 

05.03.03.02 Glecaprevir / Pibrentasvir 

Specialist use only

Use in accordance with NICE TA499

06.01.02.01 Gliclazide 

Standard release generic preparation only

06.01.04 Glucagon GlucaGen® HypoKit

See local guidelines for management of hypoglycaemia

Glucagon may also be used in management of beta blocker overdose. See "Emergency treatment of Poisoning" in current BNF and seek specialist advice from poisons centres

06.01.01.03 GlucoRx Carepoint 

Prescribe by brand for cost savings and continuity – see guidance for range of needles on formulary which are universal fitting.

09.02.02.01 Glucose Intravenous 
01.06.02 Glycerol 
02.06.01 Glyceryl Trinitrate 
01.07.04 Glyceryl Trinitrate 0.4% Rectogesic ®

Licensed for pain relief in chroic anal fissure.

Also approved for off-label indication: application to breast flaps following reconstructive surgery to prevent mastectomy skin flap necrosis

20 GLYCERYL TRINITRATE Ointment 0.2% 

This is an unlicensed preparation

 

03.01.04 Glycopyrrolate/ indacaterol inhaler Ultibro Breezhaler®
03.01.02 Glycopyrronium Seebri breezhaler®

2nd line long acting Antimuscarinic Antagonist (LAMA) after tiotropium

 

15.01.03 Glycopyrronium 
15.01.03 Glycopyrronium Liquid 1mg/5mL 

Restricted for patients with hypersalivation and swallowing difficulties.

For initation by palliative care and parkinsons teams

10.01.03 Golimumab Simponi®

In line with NICE technology appraisals and local guidance

10.01.03 Golimumab Simponi®

In line with NICE technology appraisals and local guidance

06.07.02 Goserelin 
08.03.04.02 Goserelin Zoladex®
08.03.04.02 Goserelin Zoladex® LA
03.04.02 Grass pollen extract Grazax®

Specialist initiation: paediatric or respiratory 

05.02 Griseofulvin 

Oral liquid

Specialist dermatology use only

03.01.05 Haleraid ® 
04.02.01 Haloperidol 
04.02.02 Haloperidol 
04.09.03 Haloperidol 

Unlicensed indication

Motor tics and symptoms of Tourette syndrome & related choreas

02.08.01 Heparin 
02.08.01 Heparin 

All flushes must be prescribed / documented on the drug chart

Hepsal® heparin sodium 10 units /ml as 5ml ampoules

Canusal® heparin sodium 100 units /ml as 2ml ampoules

 

14.04 Hepatitis A vaccine with Hepatitis B vaccine  Twinrix®

NOT prescribable for travel

11.05 Homatropine 

1% eye drops, 2% eye drops and 2% single use minims

Action up to three days

09.02.02.02 Human Albumin Solution 

Note: This is obtained from Pathology, not Pharmacy

14.04 Human papilloma virus vaccine Cervarix®

NHS immunisation programme via WVT

 

14.04 Human papilloma virus vaccine Gardasil®

NHS immunisation programme via WVT

 

14.04 Human papilloma virus vaccine (9-valent) Gardasil 9®

NHS immunisation programme via WVT

 

02.05.01 Hydralazine 
06.03.02 Hydrocortisone 
12.03.01 Hydrocortisone Corlan®

available for self care & over the counter purchase in primary care

13.04 Hydrocortisone 

0.5% and 1% cream and ointment

NB available OTC for short term & self limiting conditions

06.03.02 Hydrocortisone 10mg soluble tablets  

For paediatric use in adrenal insufficiency

12.01.01 Hydrocortisone Acetate 1% with Gentamicin 0.3% Gentisone® HC
11.04.01 Hydrocortisone eye ointment 

1% eye ointment and 1% eye drops

13.02.01 Hydromol ® Ointment 
09.01.02 Hydroxocobalamin 
08.01.05 Hydroxycarbamide 

Haematology - see shared care

 

09.01.03 Hydroxycarbamide Siklos®

Haematology - see shared care

10.01.03 Hydroxychloroquine 

Rheumatoid Arthritis Only

 

03.04.01 Hydroxyzine 

MHRA advice on QT interval and max doses

01.02 Hyoscine Butylbromide 
04.06 Hyoscine Hydrobromide 

Used for hypersalivation

OTC for travel sickness indication

15.01.03 Hyoscine Hydrobromide 
11.08.01 Hypromellose 

First line eye lubricant. Compliance is an important factor in successful treatment outcome.

Hypromellose 0.3% preserved & preservative free: prescribe as Evolve Hypromellose 0.3% PF 10ml.

Evolve hypromellose PF have a 90 day expiry from first opening and are preservative free 

06.06.02 Ibandronic Acid 

 150mg tablet once a month for osteoporosis

 

06.06.02 Ibandronic acid IV infusion Bondronat®

3mg/3ml pre-filled syringe for IV injection every 3 months

08.01.05 Ibrutinib Imbruvica®

Oral cancer drug (NHSE commissioned)

 

10.01.01 Ibuprofen 

Prescribing note: 1st line agent – preferred choice

10.03.02 Ibuprofen gel 
08.01.02 Idarubicin Zavedos®

Oral cancer drug (NHSE commissioned)

 

08.01.01 Ifosfamide Mitoxana®
08.01.05 Imatinib Gilvec®

 Restricted: NICE approved for CML (philidephia chromosome + ve)

04.03.01 Imipramine 
13.07 Imiquimod Aldara®

 also licensed for actinic keratosis and basal cell carcinoma

03.01.01.01 Indacaterol Onbrez

2nd line long acting Beta 2 agonist (LABA) after formoterol

02.02.01 Indapamide 

MR preparation restricted for use in stroke patients

11.08.02 Indocyanine green 

Approved for use in ophthalmology, where it is used as a diagnostic aid.

07.01.01.01 Indometacin Indocid PDA®
10.01.01 Indometacin 
10.01.01 Indometacin 
07.04.01 Indoramin 
01.01.02 Infant Gaviscon ® 
01.05.03 Infliximab 

For hospital use only

10.01.03 Infliximab Remicade®

In line with NICE technology appraisals and local guidance

13.05.03 Infliximab Remicade®

As per NICE. Consultant Dermatologist prescribing only 

06.01.01.01 Insulin Humulin® S

 3ml cartridge for Humapen® Savvio

06.01.01.01 Insulin Actrapid®

10ml vial (hospital use & insulin pumps only). All vials are for single patient use.

For local sliding scale information and hyperkalaemia guidelines see intranet

06.01.01.01 Insulin Aspart  NovoRapid®

10ml vial (hospital & insulin pumps only), 3ml cartridges (Novopen®), disposable pens (Flexpen®)

06.01.01.01 Insulin aspart Fiasp®

Very fast acting not interchangeable with NovoRapid

Consultant initiation only. 10ml vial (hospital & insulin pumps only), 3ml cartridges (Fiasp penfill®), disposable pens (Fiasp Flextouch®)

06.01.01.02 Insulin degludec Tresiba®

CAUTION: HIGH STRENGTH

Consultant initiation only – diabetes and paediatrics on an individual patient basis only, for patients who are "pre-pump" 

06.01.01.02 Insulin degludec Tresiba®

Consultant initiation only – diabetes and paediatrics on an individual patient basis only, for patients who are "pre-pump" 

Long acting insulin analogue

06.01.01.02 Insulin Detemir Levemir®

Long acting insulin analogue

3ml Cartridges (Novopen®), Disposable pens, (Flexpen®), Innolet® disposable injection device. May be used BD.

06.01.01.02 Insulin Glargine Lantus®

Semglee® disposable pens is first line biosimilar glargine.

Lantus® may be used for patients needing half unit doses.

Lantus® 10ml vial (hospital & insulin pumps only), 3ml cartridges, disposable pens (Solostar®)

06.01.01.01 Insulin Glulisine Apidra®

 3ml cartridge for Clikstar®, 3ml disposable pens Solostar

06.01.01.01 Insulin Lispro 100 units/ml Humalog®

First line is Insulin Lispro Sanofi (biosimilar). Humalog is retained on formulary for existing patients

10ml vial (hospital & insulin pumps only), 3ml cartridge (Autopen® Classic or Humapen®), disposable pens (Kwikpens®)

06.01.01.01 Insulin Lispro Sanofi biosimilar

First choice insulin lispro - prescribe by brand Insulin Lispro Sanofi

10ml vial (hospital & insulin pumps only), 3ml cartridge, disposable pens

08.02.04 Interferon Alfa 

Injectable preparation (NHSE commissioned)

 

08.02.04 Interferon Alfa Roferon-A®

Injectable preparation (NHSE commissioned)

08.02.04 Interferon Alfa Viraferon®

Injectable preparation (NHSE commissioned)

07.03.02.03 Intra-uterine Progestogen Only System Mirena®
06.02.02 Iodine and Iodide 
03.01.02 Ipratropium 
  • MDI
  • Autohaler®
  • Nebuliser solution

 

12.02.02 Ipratropium Bromide Rinatec®
03.01.04 Ipratropium bromide with salbutamol Combivent®

Nebuliser solution

02.05.05.02 Irbesartan 

 Restricted to second line agent for treatment of patients intolerant to ACE inhibitors

 

 

08.01.05 Irinotecan Hydrochloride 
09.01.01.01 Iron and Folic Acid Ferrograd Folic®
09.01.01.02 Iron Dextran CosmoFer®
15.01.02 Isoflurane AErrane®
13.02.01 Isomol® Gel 

Equivalent formulation to Doublebase gel

05.01.09 Isoniazid 

All prescribing should be consistent with national guidelines, or under the advice of specialist chest physicians or consultant microbiologists

06.01.01.02 Isophane Insulin Insulatard®

In T2DM NICE advises use of NPH insulin rather than insulin analogue first line 

May be used BD. 3ml Cartridge (Novopen®), Innolet® disposable device

 

06.01.01.02 Isophane Insulin Humulin® I

In T2DM NICE advises use of NPH insulin rather than insulin analogue first line 

 

3ml cartridge for Humapen® Savvio , 3ml; disposable pens Kwikpen®

06.01.01.02 Isophane Insulin Insuman® Basal

In T2DM NICE advises use of NPH insulin rather than insulin analogue first line 

3ml cartridge for Clikstar®, 3ml disposable pens Solostar®

02.06.01 Isosorbide Mononitrate 

BD dosing should be asymmetric i.e. morning and 14:00 hours

02.06.01 Isosorbide Mononitrate MR 

Prescribe as Mononil XL

13.06.02 Isotretinoin 

Hospital only - dermatology

 

13.06.02 Isotretinoin Roaccutane®

Hospital only - dermatology

 

01.06.01 Ispaghula Husk 
05.02 Itraconazole 

Oral and I.V. preparations

2nd line alternative when 1st line not suitable

Caution: check for drug interactions

02.06.03 Ivabradine 

Restricted to cardiologist specialists only for patients who do not tolerate beta blockers, nitrates & Calcium channel blockers antagonists (angina) and in the treatment of heart failure

 

13.10.04 Ivermectin 

 Unlicensed product 

08.01.05 Ixazomib Ninlaro®

Oral cancer drug (NHSE commissioned)

 

13.05.02 Ixekizumab Taltz®

https://www.nice.org.uk/guidance/ta442

https://www.nice.org.uk/guidance/ta537

14.04 Japanese Encephalitis Vaccine Ixiaro®
A2.01.01.01 Jevity ®  
A2.01.02.01 Jevity ® 1.5 kcal 

for tube fed patients under care of dietitian team

15.01.01 Ketamine injection 
04.07.03 Ketamine oral solution 

Pallative Care Use Only - See Shared Care

 

05.02 Ketoconazole Nizoral®

Oral.

Specialist use only

Available as an unlicensed product for the management of ectopic cushings syndrome

10.01.01 Ketoprofen Oruvail® MR

Note: Second line agent only

10.01.01 Ketoprofen 
11.08.02 Ketorolac Acular®

Macular Oedema. Continued for one month post operatively

15.01.04.02 Ketorolac Toradol®
02.04 Labetalol 
04.08.01 Lacosamide  Vimpat ®

MHRA cat 3 (prescribe generically)

01.06.04 Lactulose 
05.03.01 Lamivudine Epivir®

Antiviral for HIV or hepatitis: not suitable for primary care prescribing (NHSE commissioned)

 

05.03.01 Lamivudine Zeffix®

Antiviral for HIV or hepatitis: not suitable for primary care prescribing (NHSE commissioned)

 

04.02.03 Lamotrigine 

Off label use for mood stabilisation supported by NICE

MHRA Cat 2

04.08.01 Lamotrigine 

MHRA cat 2

08.03.04.03 Lanreotide Somatuline Autogel®

 Injectable preparation not suitable for use in Primary Care

08.03.04.03 Lanreotide Somatuline® LA

Injectable preparation not suitable for use in Primary Care

May be used "off label" to reduce output in patients with pancreatic fistula 

01.03.05 Lansoprazole 
09.05.02.02 Lanthanum Fosrenol ®

Second line phosphate binder, specialist initiation only

11.06 Latanoprost 

Prostaglandin analogues can cause changes in eye colouration and irritation

11.06 Latanoprost 0.005% with Timolol 0.5% Xalacom®
10.01.03 Leflunomide 

Restricted: Consultant rheumatologist only

08.02.04 Lenalidomide 

 ▼in line with NICE TAG 171 for the treatment of multiple myeloma in combination with dexamethasone in patients who have received two or more prior therapies. 

09.01.06 Lenograstim Granocyte®

 Injectable preparation not suitable for primary care prescribing  

08.01.05 Lenvatinib Lenvima®

Oral cancer drug (NHSE commissioned)

 

08.03.04.01 Letrozole 
06.07.02 Leuprorelin Prostap®
08.03.04.02 Leuprorelin Acetate Prostap® SR
08.03.04.02 Leuprorelin Acetate Prostap® 3
20 LEVAMISOLE Tablets 50 mg 

Unlicensed product – for the treatment of nephritic syndrome under specialist supervision  

04.08.01 Levetiracetam 

MHRA cat 3 (prescribe generically)

15.02 Levobupivacaine with Fentanyl 
09.08.01 Levocarnitine Carnitor®

NHSE commissioned for carnitine deficiency  

04.09.01 Levodopa 
05.01.12 Levofloxacin 

The widespread use of quinolones is a risk factor for C. difficile and thus the use of these agents is restricted.

Oral and I.V. preparations as per Herefordshire Antibiotic Guidelines

In patients with immediate onset penicillin hypersensitivity only. Patients with a history of a minor rash, or a rash that occurs more than

72 hours after penicillin administration are probably not allergic to penicillin and levofloxacin should not routinely be used in these patients.

04.02.01 Levomepromazine Nozinan®

Palliative Care use only [Previously methotrimeprazine (Nozinan®)]

07.03.05 Levonogrestrel Levonelle® 1500

Levonelle®1500 to be given preferably within 12 hours but no later than 72 hours after coitus

06.02.01 Levothyroxine 
02.03.02 Lidocaine 
15.02 Lidocaine 
15.02 Lidocaine  

Hospital only for acute respiratory injury, not for long term use

Primary Care - Prescribe as Ralvo®

Indicated for the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN) in adults only. (See LPT guidance)

Max use 12 hours per day re-evaluate need every 2 weeks.

Long term use not recommended.

11.07 Lidocaine 4% with Fluorescein 0.25% Minims®
06.01.02.03 Linagliptin Trajenta▼®

Use within NICE recommendations

Continue only if HbA1c is reduced by at least 0.5%within six months of starting treatment

05.01.07 Linezolid 

Hospital only, not suitable for primary care prescribing  

06.02.01 Liothyronine 

 (Triiodothyronine) hospital use for emergency hypothyroid / myxoedema crisis only – change to levothyroxine as soon as patient is stable. See Herefordshire LPT for further guidance eg NHS psychiatry use.

06.02.01 Liothyronine 

(Triiodothyronine) hospital use for emergency hypothyroid / myxoedema crisis only – change to levothyroxine as soon as patient is stable. See Herefordshire LPT for further guidance eg NHS psychiatry use.

13.02.01 Liquid and White Soft Paraffin Ointment (50:50) 
11.08.01 Liquid Paraffin eye ointment Xailin Night®

For night time use.

Contains no preservative.

Prescribe by brand in primary care / FP10 

06.01.02.03 Liraglutide Victoza®

Initiated by diabetes specialist only, in line with NICE guidance.

Continue only if a beneficial metabolic response (at least 1 percentage point HbA1c reduction and a weight loss of 3% within 6 months of starting treatment occurs and is maintained

TA203 recommendations as above for exenatide

04.04 Lisdexamfetamine Elvanse®

Consultant initiation only

02.05.05.01 Lisinopril 
04.02.03 Lithium Carbonate 

See shared care and NICE CG185 See Safer Lithium Therapy recommendations.

Prescribe by brand. If no brand specified default formulary brand is Priadel®.

Patients must be given a lithium treatment pack on initiation and encouraged to keep monitoring booklet up to date.

04.02.03 Lithium Citrate 

Lithium citrate liquid 520mg (Priadel® liquid) equiv. to 204mg lithium carbonate

Lithium citrate liquid 509mg (Li Liquid®) equiv. to 200mg lithium carbonate.

Care required when transferring between tablet and liquid formulations due to different bioavailability 

06.01.02.03 Lixisenatide Lyxumia▼®

Initiated by diabetes specialist only, in line with NICE guidance.

Continue only if a beneficial metabolic response (at least 1 percentage point HbA1c reduction and a weight loss of 3% within 6 months of starting treatment occurs and is maintained

04.03.01 Lofepramine 

Lower risk in overdose than other tricyclics 

04.10.03 Lofexidine BritLofex®

Specialist prescribing only

08.01.01 Lomustine 

Oral cancer drug (NHSE commissioned)

 

01.04.02 Loperamide 
05.03.01 Lopinavir and Ritonavir Kaletra®

All supplies of anti-retrovirals are made through Home Care under the guidance of Dr Chima-Okereke

HIV post exposure prophylaxis is available via A&E at the County Hospital – should be given after consultation with Health@Work or out of hours a consultant microbiologist

For use in post exposure prophylaxis

03.04.01 Loratadine 

Self care for minor self-limiting conditions and Hayfever.

04.01.02 Lorazepam 

Usually specialist initiated / recommended

NB 1mg lorazepam is equivalent to 10mg Diazepam

Tablets may be given sublingually

04.08.02 Lorazepam 

Intravenous preparation for inpatient use only

15.01.04.01 Lorazepam 
02.05.05.02 Losartan 

Restricted to second line agent for treatment of patients intolerant to ACE inhibitors

Losartan is 1st line "sartan" of choice

04.02.01 Lurasidone Latuda®

Occasional use, named patients only NICE ESNM48

01.06.04 Macrogol oral powder 

Prescribe as Laxido or Laxido Paediatric

Cosmocol 2nd line if lemon & lime flavour required

09.05.01.03 Magnesium Aspartate Magnaspartate®

Diarrhoea may limit the dose that can be used orally.

Contains 10mmol / sachet

09.05.01.03 Magnesium Glycerophosphate 

Diarrhoea may limit the dose that can be used orally.

Contains 4mmol / tablet (Magnaphate® / Neomag® are cost effective brands in Primary Care)

09.05.01.03 Magnesium Hydroxide Mixture BP  

Diarrhoea may limit the dose that can be used orally.

Contains 7.12 mmols magnesium in 5mls

09.05.01.03 Magnesium Sulphate 

Injection 5g in 10ml or 1g in 2ml

02.02.05 Mannitol 

Specialist use as a contrast media in radiography

 

20 Mannitol Osmohale®

For use as a diagnostic agent by Respiratory Physiology

 

05.05.01 Mebendazole 
01.02 Mebeverine 
06.04.01.02 Medroxyprogesterone Acetate Provera®

May also be used by specialist respiratory team in type 2 respiratory failure in post menopausal women (Off label)

07.03.02.02 Medroxyprogesterone Acetate Depo-Provera®
08.03.02 Medroxyprogesterone Acetate Provera®
05.04.01 Mefloquine Lariam®

Malaria prophylaxis (private: not allowed on NHS prescription)

08.03.02 Megestrol Acetate Megace®
04.01.01 Melatonin 

Licensed 2mg modified-release tablets (Circadin) first line

Restricted to CAMHS, LD, community paediatricians and occasional use in Parkinson's Disease.

Paediatrics including CAMHS: "off label" use – see shared care

10.01.01 Meloxicam 

See current guidance about the use of COX2 inhibitors. Please remember that COX2 inhibitors should not be used in patients with cardiovascular disease.

08.01.01 Melphalan 

Oral cancer drug (NHSE commissioned)

 

04.11 Memantine 

Prescribe generically

Tablets and liquid. Liquid reserved for use in swallowing difficulties 

Dementia - see shared care. May be recommended for initiation by community dementa nurses.

 

09.06.06 Menadiol Sodium Phosphate 

Restricted: For use in alcohol dependant patients only

14.04 Meningococcal A, C, W135, and Y conjugate vaccine Menveo®

NOT prescribable for travel

14.04 Meningococcal polysaccharide A, C, W135 and Y vaccine ACWY Vax®

NOT prescribable for travel

13.03 Menthol in aqueous cream 1%, 2% or 5% Menthoderm®
05.04.04 Mepacrine Hydrochloride 

Unlicensed product

09.08.01 Mercaptamine (cysteamine) eye drops  

Specialist use only for nephropathic cystinosis: NHSE funded  

01.05.03 Mercaptopurine 

Inflammatory bowel disease – see shared care 50mg tablets  

 

Oral cancer drug (NHSE commissioned) - RED

Unlicensed doses eg 10mg capsules

08.01.03 Mercaptopurine 

Inflammatory bowel disease – see shared care 50mg tablets

Oral cancer drug (NHSE commissioned) - RED

Unlicensed doses eg 10mg capsules RED

 

05.01.02.02 Meropenem Meronem®

For serious infections only as per Herefordshire Antibiotic Guidelines or consultant microbiologist recommendation

05.01.02.03 Meropenem 1g with Vaborbactam 1g Vaborem®

Microbiologist recommendation only

01.05.01 Mesalazine Pentasa®

Granules may be used for patients with swallowing difficulties

01.05.01 Mesalazine Salofalk®

 

Salofalk enema should only be used when Asacol foam enema and Pentasa retention enema are not tolerated. Its routine use cannot be justified because of the higher dosage delivered, and the higher acquisition cost.

 

01.05.01 Mesalazine Pentasa Retention Enema
01.05.01 Mesalazine Asacol®

Use for historic patients only. Prescribe as Octasa for new patients

01.05.01 Mesalazine Octasa MR
01.05.01 Mesalazine Asacol Foam Enema
08.01 Mesna 

By mouth the dose is given 2 hours before treatment with oxazaphosphorine and repeated at 4 and 6 hours after treatment 

02.07.02 Metaraminol 

unlicensed unlicensed

 

06.01.06 Meters FreeStyle®

Freestyle Precision pro 1st line for use on all wards WVT.

Freestyle Optium and Optium Ketone restricted to use for newly diagnosed patients on advice of the diabetic specialist nurses who will provide the meters and advise the patient on use – see new guidance across health economy

06.01.02.02 Metformin 

Standard release tablets and licensed oral solution 500mg/5ml (reserved for those with swallowing difficulties or enteral tubes).

Metformin should be reviewed if serum creatinine exceeds 130micromol/L and stopped if it exceeds 150micromol/L, or eGFR falls below 30ml/min

See metformin prescribing newsletter

06.01.02.02 Metformin hydrochloride MR Sukkarto® SR, Yaltormin® SR

Second line if intolerant to minimum effective dose of standard release tablets.

Prescribe as Sukkarto SR in primary care

04.10.03 Methadone 

Oral Solution 1mg/ml sugar free. Initiated & monitored by Addaction.

Tablets prescribed by Addaction only when patients travelling by air as more likely to be diverted and misused 

 

03.09.01 Methadone Hydrochloride Methadone® Linctus

For use in palliative care only

01.05.03 Methotrexate 

Rheumatology, dermatology, gastro-enterology (shared care)

RED if prescribed for cancer (NHSE commissioned)

 

08.01.03 Methotrexate 

Oral Amber – except when used in cancer regimens when RED hospital only.

Only 2.5mg tablets to be prescribed weekly for non-cancer indications

Injection - Red

10.01.03 Methotrexate 

Restricted: Initiated by consultant specialist only.

Extreme care must be taken when prescribing methotrexate:

  • Only 2.5mg tablets may be prescribed. Ensure total dose and quantity of tablets is clearly written on the prescription
  • The frequency must state once weekly (unless higher dosing is not tolerated, and the weekly dose can then be split into 3 doses per week).
  • Patients must be counselled to ensure they understand a once weekly regime. NPSA guidelines must be followed
10.01.03 Methotrexate Metoject®

Injectable product not suitable for primary care prescribing unless shared care available from out of County provider

 

13.05.03 Methotrexate 

Dermatology - see shared care

 

 

09.01.03 Methoxy Polyethylene Glycol-Epoetin Beta Mircera®

Not suitable for primary care prescribing due to complex commissioning arrangements  

13.08.01 Methyl-5-Aminolevulinate Metvix®

For Bowen's Disease. Hospital Only

02.05.02 Methyldopa 
04.04 Methylphenidate 

 See shared care for ADHD 

04.04 Methylphenidate Hydrochloride MR 

Prescribe as brand: MR caps brands are not interchangeable.

Prescribe 18mg, 27mg, 36mg, 54mg as Xaggitin® XL - equivalent to Concerta® XL. 

06.03.02 Methylprednisolone 
10.01.02.02 Methylprednisolone Acetate Depo-Medrone®
04.06 Metoclopramide 
02.02.01 Metolazone 

Specialist initiation only

02.04 Metoprolol 
05.01.11 Metronidazole 

Oral, rectal or I.V. preparations

07.02.02 Metronidazole Zidoval®

2nd line treatment only

20 Mexiletine 

 Unlicensed preparation  

05.02 Miconazole Daktarin®

Oral gel. For treatment of oral thrush only.

See section 12.3.2 - Systemic absorption may follow use of oral gel and may result in significant drug interactions

12.03.02 Miconazole Daktarin®
04.08.02 Midazolam 

Specialist Initiation

Prescribe as Buccolam 10mg/2ml strength available in 2.5mg, 5mg, 7.5mg and 10mg pre-filled syringes, colour coded for age appropriate dosing. 

Buccolam® and Epistatus® are not interchangeable and there is high risk of harm if patients receive the incorrect brand and strength of buccal midazolam.

DO NOT PRESCRIBE UNLICENSED PREPARATIONS

Licensed for under 18 years but used for adults off-label in line with MHRA

15.01.04.01 Midazolam Hypnovel®
02.07.02 Midodrine 

unlicensed unlicensed

Restricted to Age Care Consultants for use in postural hypotension when other medication has failed or is not tolerated 

 

 

07.01.02 Mifepristone Mifegyne®
02.01.02 Milrinone Primacor®
02.05.01 Minoxidil 

Cardiology specialists only. Must be used in addition to a diuretic and beta-blocker.

 

07.04.02 Mirabegron Betmiga®

2nd line agent in line with NICE

04.03.04 Mirtazapine 

15mg dose is more sedating than 30mg

01.03.04 Misoprostol 
07.01.01 Misoprostol 

Prescribing note: Please note that misoprostol is endorsed as a highly cost effective drug for termination of pregnancy and in the management of post partum haemorrhage. Both are unlicensed indications, but recommended by the RCOG guidance. It is used in preference to Gemoprost within the Trust. See link to Trust Guidelines below

 

07.01.01 Misoprostol vaginal delivery system Mysodelle®

Prescribing note: Please note that misoprostol is endorsed as a highly cost effective drug for termination of pregnancy and in the management of post partum haemorrhage. Both are unlicensed indications, but recommended by the RCOG guidance. It is used in preference to Gemoprost within the Trust. See link to Trust Guidelines below

 

08.01.02 Mitomycin 
08.01.02 Mitoxantrone  
15.01.05 Mivacurium Mivacron®
04.03.02 Moclobemide 

See BNF for specific dietary advice for moclobemide

04.04 Modafinil 

For neurology initiation in narcolepsy

Occasional use in daytime sleepiness in Parkinsons Disease  (NICE NG71)

08.02.02 Modigraf ® 

Do not prescribe for new renal transplant patients

12.02.01 Mometasone Furoate Nasonex®
13.04 Mometasone Furoate 0.1% Elocon®
03.03.02 Montelukast Singulair®

PRESCRIBE GENERICALLY

04.07.02 Morphine Zomorph®

First choice opioid for oral and sub-cut/syringe driver use.

Immediate release (IR) for titration and breakthrough pain

Prescribe modified release preparations by brand as good practice to ensure consistency of supply.

Zomorph® capsules may be opened and sprinkled onto food.

Prescribe 10mg in 1ml ampoules in primary care

04.07.02 Morphine Salts Oramorph®

Immediate release (IR) for titration and breakthrough pain

 

 

04.07.02 Morphine Salts Sevredol®

Immediate release (IR) for titration and breakthrough pain

 

11.03.01 Moxifloxacin Moxivig®

Bacterial keratitis if PF preparation required e.g. frequency more than QDS

02.05.02 Moxonidine 
09.06.07 Multivitamin  

Specialist initiation for patients on dialysis eg dietitian, renal physician

09.06.07 Multivitamin preparations Abidec®
12.02.03 Mupirocin 2% Bactroban Nasal®

For eradication or decolonisation of MRSA only

08.02.01 Mycophenolate Mofetil 

Shared care in gastroenterology & rheumatology.

Hospital only for NEW renal transplant patients

Mycophenolate may be used for the licensed indication and for unlicensed use in rheumatology, nephrology, neurology, gastroenterology, haematology and respiratory medicine only

20 Mydricaine 

Mydricaine No 2. Unlicensed drug –risk assessed 

Consultant use for sub conjunctival use to break new posterior synechae 

A5.01.01 N/A Ultra 
04.06 Nabilone 
10.01.01 Nabumetone 

Restricted: For Consultant Rheumatologist use only

02.06.04 Naftidrofuryl 

Specialist cardiology prescriptions only

 

04.10.01 Nalmefene 

Only prescribed in conjunction with continuous psychosocial support in line with NICE TA235

01.06.06 Naloxegol 

For use in line with NICE recommendation TA345

 

15.01.07 Naloxone 
04.10.01 Naltrexone 

Specialist prescribing only

50mg tablets licensed for substance misuse, other strengths are unlicensed and not appropriate for primary care prescribing

04.10.03 Naltrexone Nalorex®

Prescribing to remain with specialist

04.10 Naltrexone Hydrochloride Opizone®

Prescribing to remain with specialist

06.04.03 Nandrolone Deca-Durabolin®
10.01.01 Naproxen 

Prescribing note: 1st line agent

02.04 Nebivolol Nebilet®

Cardiology initiation 3rd line in heart failure after bisoprolol and carvedilol

 

04.07.01 Nefopam 

Specialist advice only

Occasional use for patients intolerant or allergic to opioids

A2.03.01 Neocate Active 

For infants over 12 months

A2.03.01 Neocate LCP 
05.01.04 Neomycin Sulphate 

Gastroenterology only for hepatic encephalopathy

10.02.01 Neostigmine 
15.01.06 Neostigmine 
15.01.06 Neostigmine with Glycopyrronium 
11.08.02 Nepafenac  Nevanac®

Hospital Only: postop macular oedema in patients with diabetes only

02.06.03 Nicorandil 
04.10 Nicotine Nicorette® Invisi patches

Not for FP10 prescribing. Refer all patients to Hereford council Healthy Lifestyle Trainer Service (HLTS) for behavioural support and access to pharmacotherapy. 01432 383567 healthylifestyle.trainerservice@nhs.net

NICE NG92

04.10 Nicotine Nicotinell®

Not for FP10 prescribing. Refer all patients to Hereford council Healthy Lifestyle Trainer Service (HLTS) for behavioural support and access to pharmacotherapy. 01432 383567 healthylifestyle.trainerservice@nhs.net

NICE NG92

04.10 Nicotine NiQuitin® CQ

Not for FP10 prescribing. Refer all patients to Hereford council Healthy Lifestyle Trainer Service (HLTS) for behavioural support and access to pharmacotherapy. 01432 383567 healthylifestyle.trainerservice@nhs.net

NICE NG92

04.10.02 Nicotine 

Not for FP10 prescribing. Refer all patients to Hereford council Healthy Lifestyle Trainer Service (HLTS) for behavioural support and access to pharmacotherapy. 01432 383567 healthylifestyle.trainerservice@nhs.net

NICE NG92

02.06.02 Nifedipine Adalat® LA

ONCE daily preparation

02.06.02 Nifedipine Coracten® SR

twice daily preparation

08.01.05 Nilotinib Tasigna®

Oral cancer drug (NHSE commissioned)

 

02.06.02 Nimodipine Nimotop®

Generic only. Restricted to use for subarachnoid haemorrhage.

04.01.01 Nitrazepam 

Very limited place in therapy – specialist initiation only  

Not suitable for older people due to long duration of action and subsequent high risk of falls

15.01.02 Nitrous oxide 
02.07.02 Noradrenaline / Norepinephrine 
06.04.01.02 Norethisterone 
A2.03.01 Nutramigen Puramino 
A2.02.02.01 Nutricrem®  

specialist supplements for patients with dysphagia, recommended by dietitian / SALT team

05.02 Nystatin Nystan®

For treatment of oral thrush only - See section 12.3.2 

12.03.02 Nystatin Nystan®

Oral solution

01.09.01 Obeticholic acid Ocaliva®

Hospital only medicine, not suitable for primary care prescribing 

A5.03.04 Octenilin ® Wound Irrigation Solution 
08.03.04.03 Octreotide Sandostatin®
08.03.04.03 Octreotide Sandostatin Lar®
06.04.01.01 Oestrogen only HRT implant Estradiol
06.04.01.01 Oestrogen only HRT tablet Elleste-Solo, Premarin
06.04.01.01 Oestrogens for HRT Elleste-Duet Conti®
07.02.01 Oestrogens, Topical 
07.02.01 Oestrogens, Topical Vagifem®
07.02.01 Oestrogens, Topical Ortho-Gynest®
05.01.12 Ofloxacin 

Oral and I.V. preparations

Restricted to sexual health and PID only

11.03.01 Ofloxacin Eye drops Exocin®

Restricted: Consultant use only. Effective in infections caused by Pseudomonas aeruginosa. Licensed for corneal ulcers.

13.02.01 Oilatum ®Junior Cream 
04.02.01 Olanzapine 
04.02.02 Olanzapine Embonate ZypAdhera®

Named patient use only

12.01.03 Olive Oil Ear Drops 

For self-care & over the counter (OTC) purchase in primary care

03.04.02 Omalizumab Xolair®

Injectable product not suitable for primary care prescribing 

02.12 Omega-3-Acid Ethyl Esters  Prestylon®

Consultant lipidologist initiation for refractory hypertriglyceridaemia. 

01.03.05 Omeprazole 

Prescribe as CAPSULES not tablets

01.03.05 Omeprazole IV 

For hospital use only

06.01.01.03 Omnican fine 32 gauge

Prescribe by brand for cost savings and continuity – see guidance for range of needles on formulary which are universal fitting.

Prescribe 32 gauge as significantly more cost effective than 31 gauge

04.06 Ondansetron 

Ondansetron first line post-operative anti-emetic in hospital.

Injection and suppositories restricted to secondary care use.

04.09.01 Opicapone 

 2nd line COMT inhibitor for patients unable to tolerate entacapone 

07.03.02.01 Oral Progestogen Only Contraceptives Norgeston®
09.02.01.02 Oral Rehydration Salts Dioralyte®
04.05.01 Orlistat 

Limited place in therapy – dietitian initiation only. NICE pathway

See CCG Low Priority Medicines guidance

04.09.02 Orphenadrine 

Historic use only. Only available as liquid preparation 

05.03.04 Oseltamivir Tamiflu®

As per HPA advice. See detailed guidance on the Trust intranet

08.01.05 Oxaliplatin Eloxatin®

To be used in accordance with NICE guidance

08.01.05 Oxaliplatin 

To be used in accordance with NICE guidance

20 OXANDROLONE Tablets 2.5 mg 

Restricted to Paediatric initiation

04.01.02 Oxazepam 

Short acting, useful for patients with liver failure

04.08.01 Oxcarbazepine Trileptal®

Epilepsy in line with NICE

MHRA cat 2 prescribe by brand

02.04 Oxprenolol Hydrochloride 
11.07 Oxybuprocaine Minims®
07.04.02 Oxybutynin 

Consult Local Prescribing Guidance for Management of Overactive Bladder May 2018 plus NICE for women and men

  • Non-pharmacological measures for first 3 months before considering drug therapy
  • Start at low dose and arrange four week review
  • Query need for antimuscarinics in patients with long term catheter
  • Marked negative cognitive effect in older people, particularly those with dementia (tolterodine preferred over oxybutynin if drug treatment required)

Standard Release tablets 1st line Modified release 2nd line

07.04.02 Oxybutynin Hydrochloride Kentera®

Transdermal patch Kentera® apply every 72-96 hours (twice weekly)

04.07.02 Oxycodone modified release tablets 

Oral preparation

Palliative care only for those unable to tolerate morphine or in patients with renal impairment.

Prescribe by brand as good practice to ensure consistency of supply.

HCCG brand of choice LYNLOR for standard release and OXYPRO for modified release preparations and are stocked by Out Of Hours pharmacies for emergency supplies.

 

05.01.03 Oxytetracycline 
07.01.01 Oxytocin Syntocinon®
08.01.05 Paclitaxel Taxol®
08.01.05 Paclitaxel 
08.01.05 Paclitaxel Abraxane®
08.03.04.01 Palbociclib Ibrance®

Oral cancer drug (NHSE commissioned)

 

04.02.02 Paliperidone 

Xeplion® monthly, Trevicta® 3 monthly

05.03.05 Palivizumab Synagis®

Consultant Paediatricians only

September 2012 Commissioning Policy. The use of palivizumab to reduce the risk of respiratory syncytial virus (rsv) in high risk infants as per the DOH Immunisation guide ("Green Book")

01.09.04 Pancreatin Creon® 10000
01.09.04 Pancreatin Pancrex® V
01.09.04 Pancreatin Creon® 40000

High strength formulations should be initiated by specialist

01.09.04 Pancreatin Creon® 25000

High strength formulations should be initiated by specialist 

15.01.05 Pancuronium 
04.07.01 Paracetamol 

Tablets and suspension for self-purchase in primary care unless for treatment of long term condition as per NHSE guidance

 

04.07.01 Paracetamol and codeine Co-codamol® 8/500

For self-purchase in primary care

For long term use consider prescribing "when required" codeine separately

04.07.01 Paracetamol and codeine Co-codamol® 30/500

Prescribe as Zapain in Primary Care

04.07.01 Paracetamol and dihydrocodeine Co-dydramol®

Dihydrocodeine 10mg and Paracetamol 500mg

NB other strengths of co-dydramol now available

04.08.02 Paraldehyde Enema 

Secondary Care use only

06.06.01 Parathyroid Hormone Preotact®

Injectable preparation (NHSE commissioned)

 

09.03 Parenteral Nutrition (TPN or PN) 

Manufactured solutions in use are Nutriflex® and Oliclinomel®

04.03.03 Paroxetine 

Withdrawal syndrome more common

09.01.06 Pegfilgrastim Neulasta®

Injectable preparation not suitable for primary care prescribing   

08.02.04 Peginterferon Alfa PegIntron®

Injectable preparation (NHSE commissioned)

08.02.04 Peginterferon Alfa ViraferonPeg®

Injectable preparation (NHSE commissioned)

08.02.04 Peginterferon Alfa Pegasys®

Injectable preparation (NHSE commissioned)

 

08.02.04 Peginterferon Beta-1a Plegridy®

Injectable preparation (NHSE commissioned)

 

08.01.03 Pemetrexed Alimta®
10.01.03 Penicillamine 

Rheumatology shared care

 

05.04.08 Pentamidine Isetionate Pantacarinat®

IV preparation may be given by nebuliser using suitable equipment – consult product literature

02.06.04 Pentoxifylline Trental®

Not recommended for peripheral arterial disease – NICE

Unlicensed use in gastroenterology for alcoholic liver disease

 

01.02 Peppermint Oil 

Considered 2nd line as more expensive than mebeverine

01.01.02 Peptac ® 
04.08.01 Perampanel 

Epilepsy: neurologist initiation

MHRA Cat 2 prescribe by brand

 

02.05.05.01 Perindopril erbumine or tert-butylamine 

2nd line ACEI and specific indications by cardiologists and stroke physicians

04.07.02 Pethidine 

Injection for maternity inpatient use only.

 

04.03.02 Phenelzine 

Prescribe generically

See BNF for dietary advice for patients taking MAOIs

02.08.02 Phenindione 
04.08.01 Phenobarbital 

MHRA cat 1 prescribe by brand

04.08.02 Phenobarbital injection 

Intravenous preparation for inpatient use only

01.07.03 Phenol, Oily 

Hospital use only

02.05.04 Phenoxybenzamine Hydrochloride 

Phaeochromocytoma only

Caution regarding sensitisation. Avoid skin exposure.

 

05.01.01.01 Phenoxymethylpenicillin 

 

Long term in splenectomy patients

02.05.04 Phentolamine Rogitine®, Regitin®

This is only available as an emergency item

 

11.05 Phenylephrine Hydrochloride 

10% single use minims

Contraindicated in children and the elderly due to the risk of systemic side effects May interact with systemically administered monoamine oxidase inhibitors MAOIs

11.05 Phenylephrine Hydrochloride Minims® Phenylephrine Hydrochloride

Action up to 5-7 hours

May interact with systemically administered monoamine oxidase inhibitors MAOIs

04.08.01 Phenytoin 

MHRA cat 1 prescribe by brand

Monitor serum levels, narrow therapeutic index

04.08.02 Phenytoin 

Intravenous preparation for inpatient use only

04.08.02 Phenytoin Sodium Epanutin® Ready Mixed Parenteral

Intravenous preparation for inpatient use only

A2.07 Phlexy-Vits ® 

Sachets - Under Dietician advice for tube fed patients. Can be used in phenylketonuria and similar amino acid disorders

01.06.04 Phosphates (Rectal) Fleet® Ready to use Enema
01.06.04 Phosphates (Rectal) 
09.06.06 Phytomenadione Konakion® MM

Prescribing note: May be given via a WVT PGD by authorised nurses and midwives.

09.06.06 Phytomenadione Konakion® MM Paediatric

Prescribing note: May be given via a WVT PGD by authorised nurses and midwives.

01.06.05 Picolax ® 
11.06 Pilocarpine 

Blurred vision can affect the performance of skilled tasks especially at night

Required as part of Acute Glaucoma protoco

11.06 Pilocarpine preservative free 

Blurred vision can affect the performance of skilled tasks especially at night

Required as part of Acute Glaucoma protoco

13.05.03 Pimecrolimus Elidel®

In Line With NICE TA82
On recommendation of Dermatology Specialist only. GPs may issue first prescription

06.01.02.03 Pioglitazone Actos®

May be used with insulin. Prescribe generically

Discontinue if clinically significant fluid retention occurs; contra-indicated in heart failure

05.01.01.04 Piperacillin and Tazobactam 

Neutropenic sepsis. Known Pseudomonal infection (e.g bronchiectasis, CF)

Otherwise consultant microbiologist recommendation only.

It may be used in hospital acquired pneumonia where the patient has been previously treated with co-amoxiclav. Use in other indications should be discussed with a consultant microbiologist

Please note prescriptions are monitored by pharmacy and consultant microbiologists

05.05.01 Piperazine 
03.11 pirfenidone Esbriet®

NHSE commissioned for idiopathic pulmonary fibrosis see NICE

10.01.01 Piroxicam 

Restricted: Feldene Melts are available to patients whilst nil by mouth only. Once the patient is taking oral medication, an oral preparation should be used

05.01.01.05 Pivmecillinam Hydrochloride Selexid®

Complicated UTI where other options are contraindicated or unsuitable. 

Note: there is no liquid preparation available

08.01.02 Pixantrone 
04.07.04.02 Pizotifen 
11.03.01 Polymyxin B Sulphate eye ointment Polyfax®

Effective for infections caused by Pseudomonas aeruginosa

09.01.01.01 Polysaccharide Iron Complex Miferex®

Miferex

09.02.01.01 Polystyrene Sulphonate Resins Calcium Resonium®
11.08.01 Polyvinyl Alchohol SnoTears®

First line alternative to hypromellose

Safe for contact lens wearers

11.08.01 Polyvinyl Alcohol Liquifilm Tears or Sno Tears®

Liquifilm Tears UDV first line alternative to hypromellose where preservative free required

Safe for contact lens wearers 

03.05.02 Poractant Alfa Curosurf®

For use only in SCBU.

 

 

05.02 Posaconazole (IV) Noxafil®

Hospital only antifungal agent (NHSE commissioned)

05.02 Posaconazole (oral) Noxafil®

Hospital only antifungal agent (NHSE commissioned)

 

09.02.01.01 Potassium Chloride Kay-Cee-L®
09.02.01.01 Potassium Chloride Sando-K®
09.02.02.01 Potassium Chloride 20mmol in 20ml Water For Injection 

Restricted: Ready diluted solutions can be used in any area. Concentrated potassium chloride injection is only to be used by specialist staff in critical care areas. This is a strictly enforced NPSA directive. 

09.02.02.01 Potassium Chloride 50mmol in 50mL Sodium Chloride 0.9% prefilled syringe 

Restricted: Ready diluted solutions can be used in any area. Concentrated potassium chloride injection is only to be used by specialist staff in critical care areas. This is a strictly enforced NPSA directive. 

09.02.02.01 Potassium Chloride Concentrate (Sterile) 

Only to be used by specialist staff in critical care areas. This is a strictly enforced NPSA directive.

07.04.03 Potassium Citrate 
04.09.01 Pramipexole 

Dopamine agonist (non-ergot derived) 

Prescribe standard release preparation generically and MR by brand as Pipexus® prolonged release

02.09 Prasugrel Efient®

 

 

02.12 Pravastatin  

2nd line agent. Atorvastatin 1st line.

02.05.04 Prazosin 
01.05.02 Prednisolone Predfoam

2nd line corticosteroid foam for proctitis (Budenofalk enema first line)

06.03.02 Prednisolone 

The EC tablets are not routinely available as the clinical evidence for the benefit of the EC preparation is limited. These are only available if the patient lacks dexterity to half the 5mg (2.5mg EC) or if there is a clear history of intolerance to the plain tablets

There is no rationale to use EC tablets where a PPI or H2 antagonist is also co-prescribed

Soluble tablets are only recommended for administration via feeding tubes. The standard release tablets may be dispersed in water if necessary.

11.04.01 Prednisolone 0.5% eye drops Predsol
11.04.01 Prednisolone 0.5% with Neomycin 0.5% Predsol-N®

Combination products are rarely justified except after surgery to reduce inflammation and prevent infection

11.04.01 Prednisolone Acetate 1% Pred Forte®
11.04.01 Prednisolone preservative free eye drops 

0.1%, 0.3%, 0.5% & 1%

see specials guidance

04.07.03 Pregabalin 

Titrate slowly – see guidance

Because of price structure for pregabalin, ensure dose optimisation is carried out.
Pregabalin dose spread over two daily doses proved non-inferior to three times a day dosing: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007076.pub2/pdf

04.08.01 Pregabalin 

MHRA cat 3 (prescribe generically)

15.02 Prilocaine Hydrochloride Prilotekal®
05.04.01 Primaquine 

Used in treatment of benign malarias following on from chloroquine in

P ovale and P vivax infections

08.01.05 Procarbazine 

Oral cancer drug (NHSE commissioned)

 

04.02.01 Prochlorperazine 
04.06 Prochlorperazine 
04.09.02 Procyclidine 

Short term use for patients experiencing extrapyramidal side effects to antipsychotics.

Prescribe as Kemadrin brand in Primary Care

May be stimulant and subject to misuse. Treatment over 6 months should be reviewed & gradually reduced and stopped if patients are asymptomatic

06.04.01.02 Progesterone (micronised) oral capsule Utrogestan®

Progestogenic opposition of oestrogen HRT (temporary addition due to medicines shortages Feb20)

06.04.01.02 Progesterone pessary Cyclogest®
08.02.02 Prograf ® 

Do not prescribe for new renal transplant patients

 

05.04.01 Proguanil Hydrochloride with Atovaquone Malarone® Raediatric

First line treatment of Falciparum malaria

04.02.01 Promazine Hydrochloride Promazine®
03.04.01 Promethazine Phenergan®

Prescribe generically

04.01.01 Promethazine Hydrochloride 

Sedating, mainly mental health use.

 

02.03.02 Propafenone 
11.03.01 Propamidine Isetionate Brolene® eye drops

Specific for acanthamoeba keratitis

01.02 Propantheline 
15.01.01 Propofol 
02.04 Propranolol 

Generic presentations of both standard and modified release

04.07.04.02 Propranolol 
06.02.02 Propylthiouracil 
02.08.03 Protamine Sulphate 
11.07 Proxymetacaine Minims®
01.06.07 Prucalopride Resolor®

Constipation in women in line with NICE 

05.01.09 Pyrazinamide 

All prescribing should be consistent with national guidelines, or under the advice of specialist chest physicians or consultant microbiologists

10.02.01 Pyridostigmine Bromide Mestinon®
09.06.02 Pyridoxine Hydrochloride 
05.04.01 Pyrimethamine Darprim®

Used following treatment with quinine for F malaria

04.02.01 Quetiapine 

Standard release tablets are first line.

Reserve MR tablets for acute phase initiation.

Prescribe MR tablets as Sondate XL (or Biquelle XL) brand in primary care if clinically necessary.

04.02.01 Quetiapine MR Sondate® XL

HCCG brand of choice for acute phase initiation

05.04.01 Quinine 

Dihydrochloride I.V. RED drug

Treatment of F malaria

10.02.02 Quinine 

The BNF recommends a trial discontinuation with long-term use of quinine sulfate.
Treatment should be interrupted at intervals of 3 months to assess the need for further treatment.
 

13.02.01 QV ® Intensive Ointment 
13.02.01 QV® Cream 
14.04 Rabies vaccine Rabipur®

NOT prescribable for travel

14.04 Rabies vaccine 

NOT prescribable for travel

06.04.01.01 Raloxifene Hydrochloride Evista®

Restricted to specialist initiation only, second line agent

02.05.05.01 Ramipril 

Tablets are more cost-effective than capsules at maintenance doses (Sept 18)

11.08.02 Ranibizumab Lucentis®

Ophthalmology only in line with NICE guidance TA155 and TA274

01.03.01 Ranitidine 
02.06.03 Ranolazine Ranexa®

Recommended as an option for the symptomatic treatment of patients with stable angina pectoris. Treatment should be initiated by a Cardiologist. Ranolazine should be restricted for use in patients who remain symptomatic despite treatment with all other pharmacological anti-anginal therapies and when revascularisation has been considered and undertaken or is not considered appropriate.

 

04.09.01 Rasagiline 

 Monoamine-oxidase-B inhibitors 

10.01.04 Rasburicase Fastertec®

For acute hyperuricaemia. Also approved for use in severe debilitating tophaceous gout (>3 tophi) by consultant rheumatologists

08.01.05 Regorafenib Stivarga®
15.01.04.03 Remifentanil Ultiva®
A2.05.02 Resource ® ThickenUp Clear 

See guidance

05.03.05 Ribavirin 

Specialist use only

To be used in conjunction with PEG interferon alpha in accordance with NICE Technology Appraisal 200

08.03.04.01 Ribociclib Kisqali®

Oral cancer drug (NHSE commissioned)

 

05.01.09 Rifabutin Mycobutin®

All prescribing should be consistent with national guidelines, or under the advice of specialist chest physicians or consultant microbiologists

05.01.09 Rifampicin 

I.V. and oral preparations.

All prescribing should be consistent with national guidelines, or under the advice of specialist chest physicians or consultant microbiologists.

May also be used in MRSA infections, and orthopaedic joint revisions

05.01.09 Rifampicin and Isoniazid Rifinah® 300

All prescribing should be consistent with national guidelines, or under the advice of specialist chest physicians or consultant microbiologists

05.01.09 Rifampicin and Isoniazid Rifinah® 150

All prescribing should be consistent with national guidelines, or under the advice of specialist chest physicians or consultant microbiologists

05.01.09 Rifampicin and Isoniazid and Pyrazinamide Rifater®

All prescribing should be consistent with national guidelines, or under the advice of specialist chest physicians or consultant microbiologists

05.01.09 Rifampicin, isoniazid, pyrazinamide and ethambutol Voractiv®

All prescribing should be consistent with national guidelines, or under the advice of specialist chest physicians or consultant microbiologists

05.01.07 Rifaximin Targaxan®

 Specialist gastroenterology use. For prophylaxis of hepatic encephalopathy in line with NICE

04.09.03 Riluzole Rilutek®

 For Motor Neurone Disease  in line with NICE TA20

06.06.02 Risedronate 
04.02.01 Risperidone 
04.02.02 Risperidone Risperdal Consta®
07.01.03 Ritodrine Yutopar®
08.02.03 Rituximab Truxima®
08.02.03 Rituximab MabThera®
08.02.03 Rituximab MabThera®
10.01.03 Rituximab Truxima®

In line with NICE and local guidance [for oncology/haematology use see ch.8]

10.01.03 Rituximab (rheumatology) MabThera®

In line with NICE and local guidance [for oncology/haematology use see ch.8]

02.08.02 Rivaroxaban Xarelto®

 

 

04.11 Rivastigmine 

Tablets, liquid and patch (Use Alzest® brand for patches). Liquid & patch formulations reserved for use in swallowing difficulties.

Dementia - see shared care. May be recommended for initiation by community dementa nurses.

15.01.05 Rocuronium Esmeron®
04.09.01 Ropinirole 

Specialist Initiation Only

Dopamine agonist (non-ergot derived) 

Prescribe standard release preparation generically and MR by brand as Repinex® XL or Ipinnia® XL

15.02 Ropivacaine Hydrochloride Naropin®
04.09.01 Rotigotine 

Specialist Initiation Only

Dopamine agonist (non-ergot derived).  PATCHES

Used to help control continued night-time motor symptoms despite adequate treatment with oral prolonged release dopamine agonist.

Titrate dose in steps of 2mg/24hr at weekly intervals; max dose 8mg/24hr as monotherapy up to 16mg as adjunctive therapy.

 

04.08.01 Rufinamide Inovelon®

Anti-epileptic - tertiary centres only

 

02.05.05.02 Sacubitril valsartan Entresto®

To be used in accordance with NICE guidance and to be initiated by members of the cardiology team only

 

03.01.01.01 Salbutamol 

 Prescribe generically unless specified via integrated prescribing tool i.e. ScriptSwitch

  • Pressurised metered dose inhaler (MDI)
  • Easyhaler ®
  • Easi-Breathe®
  • Accuhaler®
  • Nebuliser solution
  • Oral - specialist advice
  • Injection

 

07.01.03 Salbutamol 
03.01.01.01 Salbutamol IV 
03.01.01.01 Salmeterol 

Do NOT start for new patients and  Review current patients to consdier changing to formoterol

10.01.03 Sarilumab Kevzara®

 In line with NICE TA485

06.01.02.03 Saxagliptin Onglyza®

Use within NICE recommendations

Continue only if HbA1cis reduced by at least 0.5%within six months of starting treatment

01.07.02 Scheriproct ® suppositories 
01.07.02 Scheriproct® ointment 
13.05.02 Sebco ® 
13.05.03 Secukinumab Cosentyx®

In line with NICE technology appraisals and local guidance

04.09.01 Selegiline Hydrochloride 

Monoamine-oxidase-B inhibitors

06.01.02.03 Semaglutide Ozempic®

Semaglutide is the product of choice when a once weekly GLP-1 agonist is to be used.  

NB multidose pen delivers 4 doses ie one pen = one month supply.

Initiation dose 0.25mg once a week, then 0.5mg once a week.

When administration is with insulin: In line with NICE NG28, DSN initaition advice/recommendation should be sought when initiating GLP1 agonists in combination with insulin.  Also; in line with the SPC, caution should be exercised when considering use in patients with diabetic retinopathy treated with insulin.

06.01.01.02 Semglee® Insulin Glargine 

First choice insulin glargine, long acting analogue

3ml pre-filled disposable pen (NB no cartridge product available)

01.06.02 Senna 
04.03.03 Sertraline 

Fewer interactions and first choice in patients with cardiac disease

09.05.02.02 Sevelamer Carbonate Renvela®

phosphate binder

 

09.05.02.02 Sevelamer Hydrochloride  
15.01.02 Sevoflurane 

For paediatric induction and in adults know to be a high risk i.e. patients with myocardial ischaemia

02.05.01 Sildenafil Revatio®

Pulmonary hypertension (NHSE commissioned)

07.04.05 Sildenafil 

First line in erectile dysfunction (ED) Available to all men on the NHS from Aug 2014 ONLY if prescribed generically.

Sildenafil for Pulmonary Arterial Hypertension NHSE commissioned via specialist centres only, no GP prescribing.

Sildenafil for Raynaud’s phenomenon specialist initiation in line with NHSE algorithm

07.04.05 Sildenafil Revatio®

Pulmonary hypertension (NHSE commissioned)

 

05.03.03.02 Simeprevir Olysio®

Specialist use only

Used in accordance with NICE Technology Appraisal TA331

03.09.02 Simple Linctus, BP 

 Self Care Cough mixtures are for patient purchase only in primary care, within the "Over The Counter" (OTC) policy

03.09.02 Simple Linctus, Paediatric BP 

Self Care Cough mixtures are for patient purchase only in primary care, within the "Over The Counter" (OTC) policy

02.12 Simvastatin 

2nd line after atorvastatin.

Current evidence suggests that patient should be treated with not less than 40mg daily for secondary prevention of ischemic events [unless prescribed an interacting drug]

 

08.02.02 Sirolimus Rapamune®

Do not prescribe for new renal transplant patients

 

06.01.02.03 Sitagliptin Januvia®

Use within NICE recommendations

Continue only if HbA1cis reduced by at least 0.5%within six months of starting treatment

A2.02.02.02 Slo Milkshakes Stage 1 and 2 ®  

Mix with 200ml whole milk

For patients with dysphagia, recommended by dietitian / SALT team

A2.03.01 SMA Alfamino 
09.02.01.03 Sodium Bicarbonate 

500mg Capsules - See specials guidance if liquid required

 

09.02.02.01 Sodium Bicarbonate Min-I-Jet® Sodium Bicarbonate
09.02.02.01 Sodium Bicarbonate 

Infusion

12.01.03 Sodium Bicarbonate 

For self-care & over the counter (OTC) purchase in primary care

03.01.05 Sodium Chloride 

Sodium Chloride 0.9% - use saline injection (hospital) or

Saline Steripoule® in primary care

 

 

09.02.01.02 Sodium Chloride Slow Sodium®
11.08.01 Sodium Chloride Minims® Saline
11.08.01 Sodium Chloride 
11.08.01 Sodium Chloride 0.9% Solutions 
03.07 Sodium chloride 7% (Hypertonic) 
09.02.02.01 Sodium Chloride and Glucose Intravenous Infusion 
09.02.02.01 Sodium Chloride Intravenous 
01.06.04 Sodium Citrate 

Micolette or Micralax micro-enemas

06.06.02 Sodium Clodronate 

Restricted to haematology and oncology initiation only (Bonefos)

11.04.02 Sodium Cromoglicate 

Allergic conjunctivitis and seasonal keratoconjunctivitis

12.02.01 Sodium Cromoglicate 

For self-care & over the counter (OTC) purchase in primary care

09.01.01.01 Sodium Feredetate Sytron®
05.01.07 Sodium fusidate 

Oral preparation. Must be used in conjunction with a second anti-staphylococcal antibiotic as per Herefordshire Antibiotic Guidelines

09.08.01 Sodium Phenylbutyrate Ammonaps®

Hospital only – metabolic disorder 

01.06.02 Sodium Picosulfate 
02.13 Sodium Tetradecyl Sulphate Fibro-Vein®
04.02.03 Sodium valproate 

Episenta brand 1st line for new patients and at dose change.

See MHRA warnings on valproate in women of childbearing age

 

04.08.01 Sodium Valproate 

MHRA cat 2 prescribe by brand

Episenta - First line for new patients

 

04.08.01 Sodium Valproate Epilim® Intravenous

Hospital only

05.03.03.02 Sofosbuvir Sovaldi®

Specialist use only

Used in accordance with NICE technology Appraisal TA330

A5.01.02 Softpore  
10.01.03 Soldium Aurothomalate Myocrisin®

Rheumatology - shared care

 

07.04.02 Solifenacin Vesicare®

Not recommended for new patients but patients established on solifenacin may remain on it in line with NICE CG171. Note: 10mg dose offers minimal additional benefit over 5mg

06.05.01 Somatropin 

All prescribing to be retained by secondary care

06.05.01 Somatropin Saizen®

All prescribing to be retained by secondary care

 

08.01.05 Sorafenib Nexavar®

Oral cancer drug NHSE commissioned

02.04 Sotalol 

Included for use as a class 2 anti-arrhythmic agent only

 

02.02.03 Spironolactone 
01.08 Stoma Care 
01.03.03 Sucralfate 

(unlicensed special order product): for palliative care use only – specialist initiation

20 SUCRALFATE 2g/50ml enema 

 UNLICENSED PRODUCT – for radiation proctitis. Patient information leaflet devised – patient advice to use product essential!

 

20 Sucrose 24% Sweat-Ease®

Approved for use within paediatrics and Special Care only

15.01.06 Sugammadex Bridion®
01.05.01 Sulfasalazine 
10.01.03 Sulfasalazine 

Induction and maintenance of remission of ulcerative colitis; treatment of active Crohn's Disease.

 

Use EC tablets for rheumatoid arthritis

10.01.03 Sulfasalazine EC Salazopyrin EN-Tabs®

Can be supplied via a WVT PGD for authorised rheumatology clinical specialists (supply and monitor the use of sulfasalazine).

10.01.01 Sulindac 

Restricted: Third line agent, for initiation by consultant rheumatologists only

20 Sulphur hexafluoride  SonoVue®

Contains 8μl of sulphur hexafluoride microbubbles in 1ml on reconstitution

SonoVue is injected intravenously before the test is carried out, and is used in echocardiography to obtain a clearer scan of the chambers of the heart, especially of the left ventricle, in patients with suspected or confirmed coronary artery disease.

Use only when the results of the test without a contrast agent are inconclusive.

SonoVue is unlicensed in patients who are 18 years or younger.

SonoVue should only be used by doctors who have experience in diagnostic ultrasound imaging.

 

04.02.01 Sulpiride 
04.07.04.01 Sumatriptan 

Generically prescribed tablets 1st line. Nasal spray for paediatrics only.

08.01.05 Sunitinib Sutent®

Oral cancer drug (NHSE commissioned)

09.03 Supplementary Preparations Cernevit®

Prescribing note: TPN solutions are made in Pharmacy. For expert advice contact Andy Hedges, Pharmacy ext 2997

09.03 Supplementary Preparations Dipeptiven®

Prescribing note: TPN solutions are made in Pharmacy. For expert advice contact Andy Hedges, Pharmacy ext 2997

09.03 Supplementary Preparations Addiphos®

Restricted: Concentrated potassium phosphate injection is only to be used by specialist staff for addition to TPN solutions, and critical care. This is a strictly enforced NPSA directive. It should be treated as a Controlled Drug, and recorded as such.

09.03 Supplementary Preparations Additrace®

Prescribing note: TPN solutions are made in Pharmacy. For expert advice contact Andy Hedges, Pharmacy ext 2997

09.03 Supplementary Preparations Peditrace®

Prescribing note: TPN solutions are made in Pharmacy. For expert advice contact Andy Hedges, Pharmacy ext 2997

09.03 Supplementary Preparations Solivito N®

Prescribing note: TPN solutions are made in Pharmacy. For expert advice contact Andy Hedges, Pharmacy ext 2997

09.03 Supplementary Preparations Vitlipid N®

Prescribing note: TPN solutions are made in Pharmacy. For expert advice contact Andy Hedges, Pharmacy ext 2997

15.01.05 Suxamethonium Chloride 
08.02.02 Tacrolimus 

Do not prescribe for new renal transplant patients

13.05.03 Tacrolimus Protopic®

In Line With NICE TA82
On recommendation of Dermatology Specialist only. GPs may issue first prescription. 

07.04.05 Tadalafil Cialis®

PRN preparation only (10mg / 20mg tablets), third line for those who haven’t responded to either sildenafil or vardenafil

11.06 Tafluprost (Preservative Free) 15micrograms/ml Saflutan®

Prostaglandin analogues can cause changes in eye colouration and irritation

Preservative free preparations are reserved for patients with proven sensitivity to benzalkonium chloride.

Tafluprost only for patients intolerant to bimatoprost

08.03.04.01 Tamoxifen 
07.04.01 Tamsulosin 

CAPSULES not tablets

04.07.02 Tapentadol Palexia®

 Specialist initiation only by pain consultant

05.01.07 Teicoplanin Targocid®

Consultant microbiology recommendation only.

May be used for IVOPAT

05.03.03.02 Telaprevir Incivo®

Specialist use only

Used in accordance with NICE Technology Appraisal TA252

04.01.01 Temazepam 

Use zopiclone 1st line

15.01.04.01 Temazepam 
08.01.05 Temozolomide Temodal®
02.10.02 Tenecteplase Metalyse®

Thrombolysis in acute STEMI. May be given by paramedics

 

05.03.01 Tenofovir and Emtricitabine Truvada®

All supplies of anti-retrovirals are made through Home Care under the guidance of Dr Chima-Okereke

HIV post exposure prophylaxis is available via A&E at the County Hospital – should be given after consultation with Health@Work or out of hours a consultant microbiologist

For use in post exposure prophylaxis

05.02 Terbinafine 
03.01.01.01 Terbutaline 

 2nd line agent. Use only when patients are known to be allergic to, or poorly tolerant of salbutamol.

  • MDI
  • Turbohaler
  • Nebuliser solution

Prescribe generically unless specified via integrated prescribing tool i.e. ScriptSwitch

 

07.01.03 Terbutaline 
06.06.01 Teriparatide Forsteo®

Restricted as per NICE TA161. Prescribing and supply via hospital only

06.05.02 Terlipressin Glypressin®

Restricted to Consultant initiation only

06.01.06 Test Strips Diastix®
06.01.06 Test Strips Keto-Diastix®
06.01.06 Test Strips Multistix 8SG®
06.04.02 Testosterone and Esters Testogel®

In addition to licensed indications this may be used Off-label for reduced libido in women (1 sachet twice weekly) under the recommendation of a specialist gynaecologist

04.09.03 Tetrabenazine Xenazine® 25

Huntington’s chorea & related disorders

11.07 Tetracaine Minims® Amethocaine
15.02 Tetracaine (Amethocaine) Ametop®
06.05.01 Tetracosactide Synacthen®
09.02.02.02 Tetrastarch Tetraspan®

Restricted: ITU use only – consultant request. (NB: this replaces Voluven)

05.01.10 Thalidomide 

Named patient basis & restricted to Consultant Haematologists and

Consultant Dermatologist in specific indications

08.02.04 Thalidomide Celgene®

Named patient basis & restricted to Consultant Haematologists and

Consultant Dermatologist in specific indications

20 THALIDOMIDE Tablets 50 mg 

Named patient basis & restricted to Consultant Haematologists and

Consultant Dermatologist in specific indications

 

03.01.03 Theophylline 

Prescribe by brand

  • Nuelin SA®
  • Slo-Phyllin®
  • Uniphyllin Continus®

 

09.06.02 Thiamine Pabrinex®
09.06.02 Thiamine 
15.01.01 Thiopental 
08.01.01 Thiotepa 
06.04.01.01 Tibolone Livial®
02.09 Ticagrelor Brilique®

 

 

14.04 Tick-borne encephalitis vaccine 
05.01.03 Tigecycline Tygacil®

Consultant microbiologist recommendation only. For the treatment of complex soft tissue or abdominal infections 

11.06 Timolol 0.25%  

MHRA advise that beta blockers should not be used in patients with asthma or a history of obstructive airways disease unless no alternative treatment is available

08.01.03 Tioguanine Lanvis®

Oral cancer drug (NHSE commissioned)

 

03.01.02 Tiotropium Spiriva®

Do not exceed recommended once daily dose for tiotropium

 

Prescribe by brand to ensure continuity of product and device.

Soft Mist (Respimat device)

Spiriva Respimat® device – cost effective first line choice (soft mist)

Dry Powder devices

Braltus® Zonda device 10mcg delivered dose cost effective alternative to Handihaler (Braltus® 10mcg is equivalent to 18mcg Spiriva Handihaler)

Spiriva Handihaler® device 18mcg capsules / 10mcg dose delivered to lungs (retained for existing patients only)

 

03.01.04 Tiotropium & olodaterol ® Spiolto Respimat
02.09 Tirofiban Aggrastat®
08.01.05 Tivozanib 

Oral cancer drug (NHSE commissioned)

10.02.02 Tizanidine 

Restricted: Consultant Neurologist only

05.01.04 Tobramycin 

Use in Paediatric cystic fibrosis patients only

05.01.04 Tobramycin 

Use in Paediatric cystic fibrosis patients only.

Used in a once daily regime of 7mg/kg adjusted as per trough levels

(pre-dose trough level should be less than 1mg/litre). 

10.01.03 Tocilizumab RoActemra®

In line with NICE technology appraisals and local guidance

10.01.03 Tofacitinib citrate 

For moderate to severe rheumatoid arthritis in line with TA480

06.01.02.01 Tolbutamide 
07.04.02 Tolterodine 

Standard release - first line option

Modified release – second line option. (Prescribe as brand Mariosea® XL in Primary Care)

04.08.01 Topiramate 

Epilepsy

04.07.02 Tramadol 

Use capsules (standard release) first line. If MR necessary prescribe as brand Tramulief® in primary care

NOT recommended for routine use in primary care and should NOT be considered as an alternative to codeine/or stepping up to stronger opioids.

02.11 Tranexamic Acid 

Oral Solution & Mouthwash are available as unlicensed specials

 

20 TRANEXAMIC ACID Oral Solution 500 mg in 5mL 

UNLICENSED product. For use only when tablets cannot be swallowed.

08.01.05 Trastuzumab Herceptin®

Herceptin® – to be used in accordance with NICE guidance

11.06 Travoprost 

Prescribe generically.

Prostaglandin analogues can cause changes in eye colouration and irritation

Second line when first line prostaglandin are not tolerated

11.06 Travoprost with Timolol DuoTrav®
04.03.01 Trazodone 

Occasional use in patients with dementia

08.01.01 Treosulfan 

Oral cancer drug (NHSE commissioned)

13.06.01 Tretinoin Retin-A®

Oral cancer drug (NHSE commissioned)

06.03.02 Triamcinolone Kenalog®
10.01.02.02 Triamcinolone Acetonide Adcorty'®

Intra-articular  /  Intradermal

10.01.02.02 Triamcinolone Acetonide Kenalog®
06.01.01.03 Tricare 

Prescribe by brand for cost savings and continuity – see guidance for range of needles on formulary which are universal fitting.

 

13.07 Trichloroacetic Acid 

Trichloroacetic acid solution 20% (for orbital use). Consultant Ophthalmologists only.

Maximum of 2-3 patients a year

04.09.02 Trihexyphenidyl 

Alternative to procyclidine

05.01.08 Trimethoprim 

Oral preparation

05.01.13 Trimethoprim 
06.07.02 Triptorelin 

Decapeptyl SR first line in prostate cancer, also licensed for precocious puberty

08.03.04.02 Triptorelin Decapeptyl®

Decapeptyl SR® first line for new patients

The 3mg (one month) preparation to be stocked in hospital. Three (11.25mg) and six (22.5mg) month preparations prescribed on advice of urology team via primary care

11.05 Tropicamide Mydriacyl®

Action 4-6 hours

11.05 Tropicamide single use Minims® Tropicamide

Action 4-6 hours

06.07.02 Ulipristal Esmya®

August 2018 MHRA advice on updated liver function monitoring and appropriate use.

For pre-operative treatment of moderate to severe symptoms of uterine fibroids, dose 5mg daily for up to 3 months starting during the first week of cycle

NB Prescribe as Esmya® to avoid confusion with EllaOne® (ulipristal 30mg) See 7.3.5 Emergency contraception

07.03.05 Ulipristal EllaOne®

NB Prescribe by brand to avoid confusion with different preparations of ulipristal.

Ulipristal Acetate▼ 30mg EllaOne® can be given up to 120 hours (5 days) after coitus

03.01.02 Umeclidinium Incruse Ellipta®

2nd line long acting Antimuscarinic Antagonist (LAMA) after tiotropium

01.07.02 Uniroid HC 

Uniroid HC is cost-effective option in Primary Care

06.05.01 Urofollitropin 

Infertility Treatment, specialist supply only

 

01.09.01 Ursodeoxycholic acid Ursofalk®

250mg capsules

01.09.01 Ursodeoxycholic acid Ursogal®

150mg tablets

13.05.03 Ustekinumab 

In line with NICE technology appraisals and local guidance

06.01.01.03 v BD Autoshield Duo 

Only to be used by District Nurses (supplies via Trust)

Only on FP10 for care home nursing staff use

05.03.02.01 Valaciclovir Valtrex®

For use in sexual health and ophthalmology

05.03.02.02 Valganciclovir Valcyte®

 Specialist use only 

04.02.03 Valproic Acid Episenta

1st line for new patients and at dose change.

See MHRA warnings on valproate in women of childbearing age

05.01.07 Vancomycin 

Oral vancomycin is not absorbed. Second line for C.difficile only  

05.01.07 Vancomycin 

MRSA/multi-resistant Gram positive infections. Suspected line sepsis in paediatric oncology patients.

Blood levels should be taken before the third dose, or second dose if renal impairment is evident. A trough level of 10-15mg/l is acceptable. For serious MRSA infections, especially pneumonia, a trough level of 15-20mg/l is required

11.03.01 Vancomycin  

Consultant ophthalmologist only. See endophthalmitis protocol

07.04.05 Vardenafil Levitra®

Cost effective second line alternative to sildenafil (not available at WVT Pharmacy).

Prescribe generically

04.10.02 Varenicline Champix®

Not initiated in hospital.

Not for FP10 prescribing. Refer all patients to Hereford council Healthy Lifestyle Trainer Service (HLTS) for behavioural support and access to pharmacotherapy. 01432 383567 healthylifestyle.trainerservice@nhs.net

NICE TA123

15.01.05 Vecuronium Norcuron®
08.01.05 Venetoclax Venclyxto®

Oral cancer drug (NHSE commissioned)

 

04.03.04 Venlafaxine 

Standard release preparations are BD dosing.

Modified release (MR) capsules and tablets OD dosing.

02.06.02 Verapamil 

Not for use as an anti-arrhythmic treatment

 

04.08.01 Vigabatrin Sabril®

Epilepsy in line with NICE

 

08.01.04 Vinblastine Sulphate 

Vinca alkaloids must never be given intrathecally. This is extremely dangerous!

08.01.04 Vincristine Sulphate 

Vinca alkaloids must never be given intrathecally. This is extremely dangerous!

08.01.04 Vinorelbine 

Vinca alkaloids must never be given intrathecally. This is extremely dangerous!  

A2.01.02.01 Vital 1.5kcal 

for tube fed patients under care of dietitian

09.06.07 Vitamin and mineral supplements Forceval Soluble®

Dietitian recommendation only for tube fed patients

09.06.07 Vitamin and mineral supplements Ketovite®
09.06.02 Vitamin B Tablets, Compound Strong 
09.06.01 Vitamins A and D 
09.06.01 Vitamins A C and D 
09.06.01 Vitamins C, D and folic acid 
03.01.05 Volumatic ® 
05.02 Voriconazole Vfend®

Hospital only antifungal agent (NHSE commissioned)

 

04.03.03 Vortioxetine 

Use only after inadequate response to 2 antidepressants in current episode in line with NICE TA367

A2.05.01 VSL#3 (probiotic) 

Probiotic bacteria for the treatment of chronic, frequently-recurring pouchitis where remission is induced by antibiotics. GI consultant recommendation only

02.08.02 Warfarin 

Loading schedules must be done in accordance with haematology guidance

 

09.02.02.01 Water for Injection 
12.02.02 Xylometazoline Otrivine®

For self-care & over the counter (OTC) purchase in primary care

04.01.01 Zaleplon Sonata®

In line with NICE

05.03.04 Zanamivir inhalation Relenza®

As per HPA advice. See detailed guidance on the Trust intranet

05.03.04 Zanamivir solution for infusion 

In line with HPA guidelines https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents

13.02.01 Zerobase ® cream 

Equivalent formulation to diprobase cream

13.02.01 Zeroderm Ointment 

similar to emulsifying ointment

05.03.01 Zidovudine and Lamivudine Combivir®

Antiviral for HIV or hepatitis: not suitable for primary care prescribing (NHSE commissioned)

 

05.03.01 Zidovudine and lamivudine 

Antiviral for HIV or hepatitis: not suitable for primary care prescribing (NHSE commissioned)

 

09.05.04 Zinc Sulphate Solvazinc®
06.06.02 Zoledronic Acid 

Injectable preparation not suitable for primary care prescribing

 

06.06.02 Zoledronic Acid 4mg - hypercalcaemia/malignancy

 Restricted to haematology initiation only

04.07.04.01 Zolmitriptan 

Generically prescribed tablets and dispersible tablets. 

04.01.01 Zolpidem 

In line with NICE

04.08.01 Zonisamide Zonegran®

Capsules

In Line With NICE CG137 (Replaces TA76 and TA79)
Treatment of refractory focal seizures if initial adjunctive treatment has failed. For specialist initiation, transfer to primary care once stable.

MHRA Category 2:- The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history

04.01.01 Zopiclone 
04.02.01 Zuclopenthixol Clopixol®

Prescribe generically

04.02.01 Zuclopenthixol Acetate Clopixol Acuphase®

NOT suitable for primary care prescribing!

Short acting preparation for management of acute psychosis in secondary care (Clopixol Acuphase®) 

04.02.02 Zuclopenthixol Decanoate